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CHAPTER ONE 
BACKGROUND 
 
1.1 CANCER 
 In a healthy body, normal tissues exhibit well maintained homeostasis between 
cell death and cell proliferation. During the early years of life, normal cells divide faster 
allowing a person to grow, but on reaching adulthood most cells divide only to replace 
worn out, damaged or dying cells. When this equilibrium is disturbed, cells lose their 
ability to undergo apoptosis, proliferate in defiance to normal restraints on cell division 
and begin to grow, invade and colonize territories normally reserved for other cells. This 
type of cell behavior is characterized as “cancer”. 
 Cancer is the second leading cause of death and is responsible for one in four 
deaths  in US [1]. It is caused by either internal factors (hormones, inherited mutations 
or immune conditions) or by external factors (diet, tobacco, chemical exposure, 
radiations, infectious organisms to name a few) acting together or in sequence in the 
process of carcinogenesis. This process occurs in three phases: initiation, promotion 
and progression. During initiation, the DNA of the cell is mutated by chemical or 
physical carcinogens, leading to activation of oncogenes and/or inactivation of tumor 
suppressor genes. The second phase, tumor promotion involves clonal expansion of 
initiated cells, owing to increased cell proliferation and reduced cell death. In the third 
phase, tumor progression, tumor size increases along with invasion and metastasis. In 
this stage, additional mutations acquired confer a further growth advantage and more 
malignant phenotype [2]. 
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 Cancers can develop anywhere in the body. No matter where the cancer cells 
spread, they are characterized by tissue and cell type from which they arise. From 
histological viewpoint carcinoma arise from epithelial cells, sarcomas from connective 
tissue or muscle cells, leukemia from blood cells, and lymphomas originate in lymph 
nodes and immune system tissues. This study is focused on novel therapeutic 
strategies for pancreatic cancer (PaCa) originating from acinar ductal cells of the 
pancreas. Hence an overview of the clinicopathologic characteristics of PaCa has been 
discussed with an emphasis on the commonly occurring types of pancreatic 
carcinomas. 
 
1.2 Pancreatic Cancer 
 Pancreas is a digestive organ present deep in the abdominal area between the 
stomach and spine surrounded by liver, intestine and other organs. Pancreas can be 
divided into six cellular compartments: 1) Acinar cells produce the digestive enzymes 2) 
Ductal cells transport these enzymes to the duodenum. Both these cells together 
regulate the exocrine functions of the organ; 3) Islets of Langerhans form the endocrine 
compartment and are involved in glucose regulation by production of hormones which 
regulate the metabolic activities; 4) Supportive elements like nerves, fibrous tissue, 
vessels and other connective tissue elements play a very crucial role; 5) Ambiguous 
cells and 6) Stem cells are less well characterized and have not been clearly identified 
in histologic sections [3]. Recent reports have shown that most of the cell types that 
exist in the pancreas are associated with one or more neoplastic counterparts. 
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Figure 1: Anatomy of human Pancreas 
(Ref: Anatomy, Histology, & Embryology of the Pancreas, 2008) 
  
 Pancreatic cancer (PaCa) is the fourth major cause of cancer related death 
worldwide with an extremely low 5 year survival rate of < 5%. According to NIH-NCI and 
American Cancer Society statistics, 43,140 new cases will be detected in 2010 and 
36,800 deaths will be reported due to this disease [1]. It is also responsible for a 
substantial number of cases with carcinomas of unknown primacy [4], because it often 
escapes early diagnosis due to lack of explicit symptoms and early metastasis. Thus at 
the time of diagnosis, regional lymph node and liver metastasis of pancreatic cancer 
has already occurred, limiting the effectiveness of current therapeutic strategies.   
Risk factors for PaCa are as follows [5]: 
Age – Risk of PaCa increases with age. 90% of the patients diagnosed with PaCa are 
older than 55. 
Gender – Men are at a higher risk of getting PaCa than women. 
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Race – African Americans are more prone to this disease than are Caucasians. 
Smoking – Smokers and tobacco chewers are two to three times more susceptible. 
Obesity and exercise – Overweight people based on BMI and those who don’t get 
enough exercise are at approximately 1.7 – 2 fold higher risk of this disease. 
Diabetes – People with type 2 diabetes are at approximately two fold higher risks. In 
some patients, cancer is known to be the cause of diabetes. 
Chronic pancreatitis – People suffering from long term inflammation might also be at 
risk of PaCa. Reason is not clear but greatest in patients with inherited chronic 
pancreatitis. 
Cirrhosis of liver – Patients suffering from liver damage due to hepatitis and alcohol 
abuse are at increased risk of this disease. 
Family history – Cancer of the pancreas seems to run in some families. 
Work exposure – Heavy exposure to pesticides, certain chemicals and dyes may 
increase the risk of PaCa. 
GI disorders – Excessive stomach acids or presence of H. pylori bacteria in the stomach 
may increase the risk of PaCa. 
Diet – Increased consumption of meats, cholesterol rich foods and nitrosamines, 
increases the risk of PaCa. 
Similar to cancers of other major epithelial organs, pancreatic adenocarcinoma is 
most common in the seventh decade (mean age 63), and relatively uncommon in 
patients younger than 40 years old [6]. Invasive ductal carcinoma is the most common 
neoplasm of the pancreas, constituting >85% of pancreatic tumors that come to clinical 
attention and due to severity of this disease only 20% of the cases are deemed 
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resectable at the time of early diagnosis [6]. There are other types of invasive 
carcinomas of pancreatic ductal lineage which are studied separately from the 
conventional ductal adenocarcinoma. These include: 1) undifferentiated carcinoma, 2) 
undifferentiated carcinoma with osteoclast – like giant cells, 3) colloid carcinoma and 4) 
medullary carcinoma. 
 Noninvasive carcinomas are another group of pancreatic lesion which may be 
associated or later progress into invasive carcinoma [3].  Pancreatic Intraepithelial 
Neoplasia (PanIN) is precancerous lesion affecting the cells lining the smaller side 
branches in the pancreatic duct. There are different grades of PanIN lesions and as the 
disease progresses these lesions become severe and are a more direct indicator of 
PaCa (Figure 2). PanIN-1A microscopic lesion is the most benign type with gradual 
increments in severity leading to PanIN-3 lesions, which often evolve into PaCa. 
 
 
 
Figure 2: Histologic – genetic model for pancreatic cancer 
(Ref: Wilentz et al, 2010) 
  By the time a patient is diagnosed with this disease, PaCa has often spread and 
is already in advanced stage, thus a large majority of patients are not suitable for 
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surgical interventions. Efforts are consistently being made in diagnosing this disease in 
its early stages, which will help us to detect PaCa while they are clinically manageable 
by surgery. 
 
1.3 Genetic alterations in pancreatic cancer 
 Carcinogenesis is a multistep process where several pathways are deregulated 
and genome stability is compromised. Considerable progress in the identification and 
characterization of somatic and/or germline genetic alterations have provided a limited 
understanding as regards to the mechanistic basis of this multigenic mutational disease. 
Distinct chromosomal aberrations such as amplification, deletion or hypermethylation 
are often unified with smaller, more subtle alterations affecting the open reading frames 
of proto-oncogenes, tumor suppressors, and genome caretaker genes dictating the 
overall development of this disease [7-10] (Figure 3). Although the frequent expression 
of specific genes might be associated with distinct events at each stage of pancreatic 
carcinogenesis, pancreatic tumors harbor heterogeneous mutational backgrounds that 
give each tumor a unique molecular signature leading to very little variation in clinical 
outcome. 
 
Oncogenic mutations 
 Oncogenes are derivatives of normal cellular genes called proto-oncogenes. 
These oncogenes are either constitutively active or become active under specific 
conditions and play critical role in cell growth and differentiation by maintaining cellular 
transformation. One of the main oncogenes involved in pancreatic cancer is K-ras 
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(12p12. 1) which functions as a GTP- binding second messenger in growth factor 
receptor signaling pathways enhancing the transition through the G1 phase of the cell 
cycle. Somatic mutations can alter the GTP-binding pocket, thus deregulating the ability 
of K-ras to dephosphorylate GTP, rendering the protein constitutively active. 95% of 
pancreatic cancers have K-ras mutations, representing the highest fractions of any 
tumor type [11]. Gain-of-function owing to mutation of K-ras has been reported to occur 
in a great majority of pancreatic adenocarcinomas leading to the activation of 
transcription factor NF-κB [12]. Normal pancreatic tissue rarely harbors mutations in the 
K-ras oncogene [13], whereas activation of cellular pathways involving ras is essential 
for pancreatic carcinogenesis and occurs early during the development of pancreatic 
malignancy [14]. 
 
Growth factor signaling cascades 
 The deregulation of certain genes suggests a key role for them in the 
development of pancreatic cancers. Several reports have confirmed that the stimulation 
of EGFR, PTCH HedgeHog receptor, IGF-IR, and PDGFRs signaling by their 
corresponding ligands through autocrine and paracrine loops contributes to the 
sustained proliferation, survival, migration, and metastasis of pancreatic cancer cells 
[15]. The activation of these growth factor receptors results in the stimulation of 
distinctive mitotic and antiapoptotic signaling cascades, which get co localized at close 
proximity in the microdomains of the plasma membrane, thus playing an important role 
by allowing a more rapid transduction of the mitogenic and survival signals. 
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Epidermal Growth Factor Receptor signaling cascades 
 EGF is a polypeptide and one of the maintaining factors in continuous renewal of 
epithelial cells by binding to its receptor EGFR. The latter is characterized by its ligand 
dependent tyrosine kinase activity, and the subfamily consists of four closely related 
receptors: ErbB/ HER 1- 4. Coexpression of EGFR and its ligands EGF and TGF-α, in 
pancreatic cancer has been notably recognized as a molecular event linked with tumor 
growth, metastasis and a decrease in survival span and is reported to occur in 38% of 
human pancreatic carcinomas [16-18]. 
 Reports have shown that the enhanced activation of EGFR signaling in 
pancreatic cancer could be in part by the down regulated expression of EGFR-related 
protein (ERRP), a negative regulator of ligand induced EGFR activity [19]. Sustained 
activation of EGF-EGFR systems assumes a crucial role in pancreatic cancer 
progression. This activation leads to stimulation of numerous mitotic, antiapoptotic and 
angiogenic signaling cascades including MAPK, PI3K/Akt, Src, NF-κB, and the 
coreceptor for VEGF, neuropilin-1(NRP-1) which contributes in the sustained 
proliferation, survival and metastasis of cancer cells. 
 
Sonic Hedgehog, Notch, and Wnt signaling cascades 
 The aberrant reactivation of distinct developmental signaling pathways like Sonic 
Hedgehog, Notch and Wnt in cancer epithelial cells and the molecular crosstalk 
between these mitogenic cascades plays a major role in the initiation and progression of 
pancreatic cancer [20-22]. Briefly, the activation of GL1 transcription factor causes the 
upregulated expression of Indian and Sonic Hedgehog ligands in pancreatic cancer. 
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Similarly, the reactivation of Notch pathway in epithelial cells contributes to the initiation 
of pancreatic tumorigenesis at the earliest phases. In addition, a defect in Wnt/β-catenin 
signaling through β-catenin stabilization also occurs in pancreatic ductal neoplasms. 
However, the establishment of specific functions associated with enhanced activation of 
Wnt/β-catenin requires further in depth studies. 
 
Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF), the most well-characterized 
angiogenic factor, is known to play a vital role in tumor associated microvascular 
invasion [23-25]. In human pancreatic cancer, VEGF has been found to be over-
expressed [25, 26]. Many studies have documented that VEGF is a critical mediator of 
angiogenesis and regulates most of the steps in the angiogenic cascade including 
proliferation, migration, and tube formation of endothelial cells [27, 28]. VEGF exists, at 
least, in six isoforms with variable amino acid number produced through alternative 
splicing. 
VEGF is subjected to multi-level regulation to ensure proper expression under 
physiologic and pathologic conditions. Numerous studies have been devoted for 
understanding the mechanism by which VEGF expression can be regulated at the 
transcriptional level. A wide range of cytokines, oncogenic proteins or transcription 
factors such as insulin-like growth factor1 (IGF-1), transforming growth factor β (TGF-β), 
c-Src, Ras, NF-κB and SP1, regulate VEGF gene transcription [29-31]. Hypoxic 
condition can also affect VEGF mRNA stability [32] and translation initiation [33]. 
Extracellular cleavage of VEGF by uPA or plasmin and processing by MMPs can 
regulate its mitogenic effect, bioavailability and vascular patterning in tum
These multi-level regulated patterns of 
angiogenesis induced by tumors.
 
Mitotic and survival signaling cascades
Mitogen Activated Protein Kinase
 EGFR and other growth receptors stimulate the 
expression of numerous mitotic genes
pancreatic cancer cells. Unlike 
development, MAPK pathway contributes not only in triggering the proliferative signals 
in pancreatic cancer cells, but also seems to be absolutely essential for the survival of 
metastatic cancer cells. 
 
                   
Figure 3: Disruption of signaling mechanisms in cancer
 
 
  
- Limitless potential for 
replication, angiogenesis, tissue 
invasion and metastasis
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VEGF provide various targets for the inhibition of 
 
 
 (MAPK) 
MAPK cascade, 
 involved in growth, survival and invasion
K-ras which is required in the initial stages of can
 
 
- Evading apoptosis and 
insensitivity to antigrowth 
signals
ors [34, 35]. 
leading to the 
 of 
cer 
 
PI3K/Akt signaling  
 As mentioned previously, gain
pancreatic carcinogenesis [14
resulting in the activation of various 
PI3K/Akt  pathway. PI3K phosphorylates serine/threonine kinase 
thereby controls the transcription of genes involved in cell survival
regulates a variety of cellular functions in carcinogenesis, such as growth, cell cycle 
progression, apoptosis and cell migration
 
NF-κB signaling cascade 
 Transcription factor NF
regulates several downstream growth factors and seems to be constitutively active in 
about 67% of pancreatic adenocarcinomas but not in immortalized, 
pancreatic epithelial cells [38]
 
Figure 
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-of-function mutation of K-ras 
] which causes the downstream activation of 
proliferation linked signaling, one of them being 
PKB/Akt
 [36]. 
 [37]. 
-κB is a family of pleiotropic transcription factors that 
non
 (Figure 4).  
 
4: NFκB linked Diseases 
is crucial for 
p21 protein 
, which 
PI3K cascade 
-tumorigenic 
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 NF-κB regulates the expression of a wide array of genes involved in growth, 
proliferation, metastasis, differentiation, apoptosis and inflammation. Activation of EGF-
EGFR cascade causes the stimulation of NF-κB1 (p50)/Rel A (p65) in some pancreatic 
cancer cells. Binding with inhibitor protein IκBα, controls and regulates the dissociation 
and translocation of active NF-κB to the nucleus. On translocation of NF-κB to the 
nucleus, several genes get activated leading to enhanced activity of pro-inflammatory 
and pro-oncogenic messenger molecules such as TNF-α, IL-1, IL-6, COX-2, and cyclin 
D1 [39].  
 Several reports suggest that the main mechanism for NF-κB to promote 
pancreatic cancer growth is via inhibition of apoptosis [40-42]. Additionally, recent works 
have also revealed that radiation or chemotherapy can evoke cellular stress that causes 
the activation of NF-κB, promoting tumor cell survival. This has been identified as one 
major cause limiting therapy in PaCa patients [39]. 
 
Cyclooxygenase activity 
Cyclooxygenase (COX) is the enzyme catalyzing the first two steps of synthesis 
of the prostaglandins from arachidonic acid. There are two isoforms of this enzyme 
which are similar in structure and activity, but COX-1 is constitutively expressed in most 
tissues whereas COX-2 is absent under normal physiological conditions and is rapidly 
expressed as a result of stimulation by growth factors, cytokines, inflammatory 
mediators and tumor promoters [43]. 
COX-2 mRNA increases by more than 60 fold in pancreatic cancer as compared 
to adjacent non tumorous tissue, and reportedly present in 90% of pancreatic cancers 
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[44]. The exact mechanism by which COX-2 promotes pancreatic carcinogenesis is not 
clear, but is speculated to increase VEGF production and cell proliferation through an 
autocrine mechanism, inducing angiogenesis and invoking anti-apoptotic effect [43]. 
 
Matrix metalloproteinase 
Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases 
are critically involved in the processes of tumor cell invasion and metastasis [45-47]. 
Tumor metastasis occurs by a series of steps including cell invasion, degradation of 
basement membranes and the stromal extracellular matrix ultimately leading to tumor 
cell invasion and metastasis [48, 49].  MMPs are proteinases that hydrolyze a variety of 
extracellular matrix protein, which are considered to be important factors in the spread 
of tumor [49-51]. Among these MMPs, matrix metalloproteinase-9 (MMP-9, gelatinase 
B, Mr 92,000 type IV collagenase) has been shown to be highly expressed in pancreatic 
cancer [46, 52, 53] 
Pancreatic cancer patients with over expression of MMP-9 revealed a trend 
towards poor prognosis than those who did not express it [54]. MMP-9 is also thought to 
play a role in the degradation of basement membrane collagen IV and, hence, may 
contribute to the invasive ability of pancreatic cancer cells. Previous studies 
demonstrated that MMP-9 expression can be induced by a variety of stimuli, including 
transforming growth factor-β, and epidermal growth factor through NF-κB pathway in 
pancreatic cancer cells [55]. Inhibition of MMP-9 expression and/or activity results in 
reduction of tumor invasion and metastasis in animal studies [56]. Therefore, MMP-9 is 
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considered to be an important factor in facilitating invasion and metastases in 
pancreatic cancer. 
 
Mutations in tumor suppressor genes 
 Tumor suppressor genes normally function to prevent uncontrolled cellular 
growth. A minimum of 11 tumor suppressor genes have been identified in human 
cancers, with inactivation of genes p16, SMAD4 and p53 as common events in the 
development and progression of pancreatic cancer [14, 57, 58].  p16 (9p21.3) is a 
cyclin-dependent kinase inhibitor that binds to cyclin-dependent kinase 4(CDK4). This is 
one of the most classical tumor suppressor genes which are most frequently altered in 
cancers. It normally regulates cell cycle progression by inhibiting the Cyclin D1-CDK4/6 
responsible for G1/S transition by regulating the ability of retinoblastoma tumor 
suppressor protein (Rb) to prevent cell proliferation. As discussed previously, mutation 
of K-ras occurs early on during pancreatic carcinogenesis, whereas alteration of p16 is 
associated with the progression of malignancy [59]. This mutation increases the 
selective advantage of subsequent mutation in SMAD4 [60]. 
 Some genetic mutations are not always required, but provide a supportive role in 
development or progression of cancer. SMAD4 is one such gene which gets inactivated 
in almost 45% of pancreatic cancers, but less common in other cancer types. SMAD4/ 
DPC4 is a tumor suppressor protein which translocates to the nucleus to activate 
expression of genes involved in growth inhibition [61] and mediates the downstream 
effects of TGF-β-signaling pathway [62] which is otherwise involved in regulation of 
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several cellular processes such as cell division, differentiation, motility, adhesion and 
apoptosis [63]. 
 Another frequently altered gene in almost all cancers is TP53 (p53, 17p13.1). 
p53 is a tumor suppressor gene which plays a very crucial role in regulating cell cycle 
during DNA damage by upregulating the expression of genes in response to cellular 
stresses. p53 also directly influences cell cycle machinery by inducing p21(WAF1/CIP1) 
which in turn negatively regulates CyclinD/Cdk, thereby arresting cells in the G1 phase 
of cell cycle and inhibiting cell growth. Mutations in p53 gene occur in almost 70% of 
pancreatic tumors. Deletion of p53 by itself does not develop pancreatic neoplasias, but 
combining it with K-ras activation leads to a rapidly progressing and lethal pancreatic 
adenocarcinoma phenotype [60]. 
 A network is established by the crosstalk between oncogenes, tumor suppressor 
genes and many other signaling molecules contributing to the molecular pathogenesis 
of PaCa, suggesting that targeted inactivation of these important signaling pathways 
could be a novel and newer approach for the prevention and/or treatment of PaCa. 
Some other genes which are not capable of inducing cancer by themselves but 
crosstalk with certain signaling pathways or stages of cancer progression and confer an 
important role in synergism with the other major pathways as listed below. 
 
Cell cycle checkpoints 
 Various proteins are involved in the regulation of cell cycle. Regulating cell cycle 
commitment is a very important step which helps in maintaining the balance at different 
check points. The retinoblastoma protein (Rb) plays a crucial role in controlling this 
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event by its association with E2F. When the cells need to undergo a cell division, the 
growth factors are stimulated which cause the release of E2F from pRb, allowing the 
expression of S-phase critical genes. However when cells are not stimulated to divide, 
pRb inhibits E2F transcriptional activity thereby restricting the progression in cell cycle. 
Though it plays a very important role, it is rarely mutated in pancreatic cancers [64].  
Cyclin D1 works in association with either cyclin dependent kinase 4 or 6 to 
phosphorylate and inactivate pRb.  
 Several reports have been published with different mutation frequencies for this 
gene, but the discrepancies in frequencies between these studies are not readily 
explained. Another cyclin, Cyclin E1 combines with Cdk2 causing phosphorylation of 
several substrates important for G1/S transition and DNA replication activities. Cyclin E1 
is found to be overexpressed in ~6% of pancreatic cancers. 
 
Double stranded DNA break repair 
 Sequence integrity of the genome is very important for normal cells to thrive, 
which would otherwise be predisposed to cancer. A special class of genes known as 
genome- maintenance genes plays a primary role in DNA repair and maintenance. 
BRCA2 participates with Rad51 and BRCA1 to prevent and/or repair DNA double 
stranded breaks through homologous recombination. Studies show that if this inactive 
allele is inherited, it confers a 3.5 to 20 fold increased risk of developing pancreatic 
cancer [65]. The mutational frequency for the homozygous inactivation of this gene has 
been found to be ~7% in pancreatic cancers [66]. 
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Apoptosis 
 Apoptosis is a hallmark of cancer progression. Cell survival is regulated by the 
balance between pro-apoptotic and anti-apoptotic stimuli. Dysregulations in the 
apoptotic pathway can alter this equilibrium, which is the key step in carcinogenesis. 
The entire apoptotic mechanism is interplay of several molecules. The tumor 
suppressor protein p53 is one of many proteins that contributes to the activation of the 
intrinsic signaling pathway [67]. Inactivation of this protein or the p53 pathway 
(upstream activators and/or downstream effectors), due to mutation, is seen in as many 
as half of all human cancers [68]. Promoting the alternative extrinsic pathway, operating 
independently of p53 or activation of downstream molecules in the intrinsic signaling 
pathway may be the mechanism by which anti-cancer agents can trigger apoptosis.  
 
MicroRNA in Pancreatic Cancer 
Pancreatic cancer is a fatal disease and is usually diagnosed at a later stage, 
mostly when the tumor has already advanced to an unresectable stage. Recent 
research has shown that expression patterns of miRNAs are a richer source of 
pathognomonic tumor profiling compared to messenger mRNA expressions. 
miRNA are a family of highly conserved, non-coding, 17-25 nucleotide long RNA 
products, that play an important role in controlling gene expression at the post 
transcriptional level [69].  Biosynthesis of miRNAs is a multistep process occurring in 
both the nuclear and cytoplasmic compartments of the cell (Figure 5). Initially, miRNAs 
are transcribed into a longer several kilobase pair primary transcript (pri-miRNA) by 
RNA polymerase II. The pri-miRNA has a characteristic 5’ 7- methyl guanylate (m7G) 
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cap and a 3’ poly (A) tail [70, 71]. This pri-miRNA is processed in two stages resulting in 
the formation of mature miRNA [72]. In the first step Drosha/ DGCR8, a ribonuclease III 
endonuclease cleaves the pri-miRNA into a 65-70 bp stem loop precursor miRNA (pre-
miRNA) in the nucleus [72-74]. The pre-miRNA is then transported to the cytoplasm by 
Exportin-5-RanGTP dependent mechanism [75] where it undergoes a series of cuts to 
generate a mature RNA duplex by RNase III endonuclease Dicer/ TRBP and AGO2 [76, 
77]. A pictorial representation of the sequence of events leading to biogenesis of miRNA 
is shown below. 
 
 
Figure 5: Biogenesis of microRNA 
(Ref: Chen, 2005) 
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The helicase activity causes the RNA duplex to unwind and mature resulting in 
the formation of a single stranded miRNA which enters into the RNA-induced silencing 
complex (RISC) [78]. This combination then targets mRNA through a poorly defined 
mechanism. Depending on the complementarity between the two regions the fate is 
decided. Perfect base pairing is extremely rare but if strong base pairing is present 
between the 5’ half of the miRNA i.e., the “seed” region nucleotides 2-8, and its target 
may be sufficient to mediate mRNA regulation in animals [79]. 
Partial complementarity between the seed region of miRNA and 3’UTR region of 
the target gene leads to translational inhibition [80], whereas perfect complementarity 
results in target mRNA degradation [81]. Since there is no specific complement 
sequence to target, each miRNA is predicted to target an average of 200 genes. The 
genomic distribution of miRNAs is discrete and represents 1-3% of the human genome, 
controlling 20-30% of the protein-coding genes in the human genome. Approximately 
70% of the miRNAs are located in the introns and/or exons while the remaining 30% are 
situated in intergenic regions or gene deserts [82]. 
Transcriptional regulation of miRNA expression is controlled by the host tissue 
genes, which make their expression tissue specific, or regulated independently via their 
own regulatory elements. Several studies have documented the presence of miRNA 
genes in genomic regions associated with cancer, chromosomal break points, as well 
as in the minimal regions of the loss of heterozygosity/ amplifications, suggesting their 
role in human tumorigenesis [83]. Depending on the tissue and progression of cancer, 
miRNA can function as oncogenes or tumor suppressor. The exact mechanism of action 
of miRNAs is not very well documented, but CpG methylation is one of the epigenetic 
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mechanisms for miRNA deregulation in cancer tissue. Therefore, a thorough analysis of 
miRNAs in tumor cells could help us in restoring the expression of healthy genes 
provoking malignant cells to revert into either a benign or normal state. 
miRNA profiles can be studied and quantified using a number of approaches, 
including cDNA arrays [84], Invader assay [85] and Real time PCR [84]. Using these 
advanced technologies, several studies have recently shown the deregulation of miRNA 
expression in pancreatic cancer tumor tissues and this information might be useful in 
differential diagnosis of pancreatic cancer from other tumors. For example, miR - 375 
and - 376 expressions were significantly high in the mouse pancreas and pancreatic 
islet cells as compared to brain, heart and liver tissue [86]. Studies have documented 
the significant up regulation in miR-21 levels in pancreatic cancer [87-89]. 
Another advanced study using the QuantiMir system analyzed the differential 
expression of 95 miRNAs in 10 pancreatic cancer cell lines and 17 pairs of pancreatic 
cancer/normal tissues. A significant up regulation of miR-196a, miR-190, miR-186, miR-
221, miR-222, miR-200b, miR-15b, and miR-95 in most pancreatic cancer tissues and 
cell lines was reported. The up regulation of these eight miRNAs ranged from 70 – 
100% between normal control and tumor cells or tissues [90]. 
Gusev et al., analyzed and predicted miRNA targets and recommended that co-
expressed miRNA collectively provide abnormal phenotypic changes in cancer cells by 
either targeting the function and/ or the signaling pathways known to be affected in a 
particular cancer [91]. MiRNA expression profiling may generate a unique molecular 
signature for any given cancer type. However, pancreatic cancer therapy still remains a 
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major challenge to all clinicians. This is a uniformly fatal disease and creates a major 
hurdle due to its late diagnosis and limited therapeutic options. 
 
Pancreatic cancer treatment 
There are some standard treatment options for patients with pancreatic cancer. 
 
Surgical treatment 
Potentially curative surgery is done when diagnostic tests suggest that it is 
possible to remove the entire tumor.  This attempt might be successful in some patients, 
since only about 10% of pancreatic cancers are present entirely within the pancreas at 
the time of diagnosis. In situation, when there appears to be no further spread beyond 
the pancreas, cancer cells might have already disseminated to other parts of the body. 
Approximately 30 to 50% patients may suffer from complications due to surgery, such 
as leakage from various surgical connections, infections and bleeding. 
 
Radiation treatment 
Patents with resectable pancreatic cancer are often subjected to radiation before 
or after the surgery. Radiation therapy is often given along with other treatment 
modalities to increase the effectiveness of the treatment. 
 
Chemotherapeutic treatment 
Less than 20 percent of patients with pancreatic cancer are candidates for 
surgery, because the disease is often detected in the late stages. In such cases, 
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chemotherapy is often used since pancreatic cancers have already metastasized. The 
scheduling of chemotherapy is based on the type of cells, rate at which they divide, and 
the time at which a given drug is likely to be effective.  This is why chemotherapy is 
typically given in cycles. Unfortunately, chemotherapy does not know the difference 
between the cancerous cells and the normal cells.  Chemotherapy will kill all cells that 
are rapidly dividing.  The "normal" cells will grow back and be healthy but accompanying 
side effects occur.  The "normal" cells most commonly affected by chemotherapy are 
the blood cells, the cells in the mouth, stomach and bowel, and the hair follicles; 
resulting in low blood counts, mouth sores nausea, diarrhea, and/or hair loss.  Different 
drugs may affect different parts of the body [92]. 
PaCa cells do not harbor normal checks and balances in place that control and 
limit cell division.  The process of cell division in all kinds of cells, whether normal or 
cancerous, is through the cell cycle; hence the ability of chemotherapy to kill cancer 
cells depends on its ability to halt cell division.  Usually, the drugs work by damaging the 
RNA or DNA that dictates the cell how to copy itself through cell division.  If the cells are 
unable to divide, they die.  The faster the cells are dividing, the more likely it is that 
chemotherapy will kill the cells, causing the tumor to shrink and  inducing cell suicide or 
apoptosis [93]. 
 
Figure 6: Chemical Structure of Gemcitabine 
  Gemcitabine has been a standard treatment for patients with advanced (and 
inoperable) pancreatic cancer for a decade. 
family of drugs called antimetabolites, which are cell
normal substances within the cell attacking them at very specific phases in the cycle. 
When the cells incorporate these su
unable to divide.   Chemically gemcitabine is a nucleoside analog in which the hydrogen 
atoms on the 2' carbons of   deoxycytidine are replaced by fluorine atoms thus 
intracellularly converting to the active 
triphosphate (dFdCDP, dFdCTP)
thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is 
incorporated into DNA, resulting in DNA strand 
7). 
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Mechanistically, gemcitabine belongs to the 
-cycle specific and very similar to 
bstances into the cellular metabolism, they are 
metabolites difluorodeoxycytidine di
 (Figure 6). dFdCDP inhibits ribonucleotide reductase, 
termination and apoptosis 
 
 
7: Gemcitabine metabolism 
- and 
[94] (Figure 
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 Although gemcitabine remains the backbone of chemotherapy in pancreatic 
cancer, it has only a 5.4% partial response rate and imparts a progression-free survival 
interval ranging from 0.9 to 4.2 months [95]. Many patients diagnosed with pancreatic 
cancer show initial sensitivity to gemcitabine therapy followed by the rapid development 
of resistance—a feature that essentially characterizes this fatal disease. Several 
mechanisms have been proposed for acquired chemoresistance after gemcitabine 
treatment. HMGA-1 is an architectural transcription factor often upregulated in 
pancreatic cancer and is known to promote chemoresistance through Akt dependent 
mechanism [96]. Development of resistance is also associated with alteration in 
activities of enzymes such as deoxycytidine kinase, which is involved in drug 
metabolism [97, 98].  
 Although the rapid acquisition of resistance to gemcitabine treatment inevitably 
translates into poor patient outcomes, the tumor's initial vulnerability and subsequent 
resistance strongly suggest either the preexistence of resistant cell subpopulation(s) or 
the rapid development of resistant cells from the tumor itself or from tumor/stromal 
alterations. Thus, a better understanding of the origins of gemcitabine resistance is 
critical to the development of superior combination therapies or replacement of 
gemcitabine as the gold standard in pancreatic cancer. Several genetic and/or 
epigenetic alterations have been associated with gemcitabine resistance. Not 
surprisingly, these include gene products associated with gemcitabine transport and 
metabolism. 
 However, a more optimistic possibility is that targeted therapy aimed at critical 
common elements in resistance will restore sensitivity. Gemcitabine can be used as a 
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neoadjuvant and adjuvant therapy along with other agents which can work 
synergistically to reduce the effect of chemo resistance providing long term benefits. 
 
Nutrition and pancreatic cancer 
 It is important for the human body to maintain a balance between the oxidant-
antioxidant levels in the body for ideal cell regulation and reduced inflammation. Several 
bioactive food components have been documented over centuries for their crucial role 
in maintaining a homeostasis in cell proliferation and integrity.  The contribution of diet 
and nutrition to cancer risk, prevention and treatment has been a major focus of 
research in recent years because certain nutrients and dietary agents appear to protect 
the body against diseases such as cancer.  
 A healthy diet can act as multimodal cancer prevention strategy. Buiatti et al [99] 
determined that individuals who consumed more meats, salted fish, cold cuts and 
seasoned cheeses had the highest risk of gastric cancers, while those consuming more 
fresh fruit, raw vegetables, onion, garlic and spices were associated with a lower risk. 
Some of the spices commonly used in the diet are obtained from different parts of plants 
such as fruits, bark, roots or leaves. 
 Curcumin obtained from the spice turmeric is known to possess anti-
inflammatory, anti-proliferative, and anti-angiogenic properties. Anti-carcinogenic 
properties of curcumin have been very well documented and have shown to be a potent 
agent against pancreatic cancer. In this study, curcumin was used as a positive control 
to evaluate the anti-cancer properties of a novel bioactive compound, garcinol. 
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Garcinol 
Garcinol, harvested from Garcinia indica (Family: Clusiaceae; Genus: Garcinia), 
has traditionally been used in ayurvedic medicine. The genus Garcinia includes some 
200 species found in the tropics, especially Asia and Africa [100]. It has many culinary, 
pharmaceutical and industrial uses; however its biological properties are only beginning 
to be elucidated [101]. The plant grows extensively on the western coast of India and is 
known by various names across the world, such as Mangosteen, wild Mangosteen, or 
Red Mango (Figure 8).  
Extracts from Garcinia indica are rich in polyisoprenylated benzophenone 
derivatives such as yellow colored Garcinol and its colorless isomer, Isogarcinol. These 
derivatives are primarily found in the rind of the fruit along with other components such 
as hydroxycitric acid (HCA), hydroxycitric acid lactone, citric acid and oxalic acid. The 
fruit also contains other compounds including malic acid, polyphenols, carbohydrates, 
anthocyanin, pigments and ascorbic acid [102]. Garcinol with a molecular weight of 602, 
is the active principle of Garcinia indica, which is crystallized out as yellow needles 
(1.5%) from the hexane extract of the fruit rind.  
 
 
Figure 8: Mangosteen fruit – source of garcinol 
 
27 
 
 
Putative role of garcinol as a free radical scavenger and anti-ulcer agent was 
tested by Nakazawa et al. Garcinol suppressed hydroxyl radical, superoxide anion and 
methyl radical suggesting its ability to scavenge both hydrophilic and hydrophobic ones 
including reactive oxygen species. In this study, garcinol was shown to be three times 
more effective in free radical scavenging than DL-R-tocopherol [103, 104].  
Garcinol (Figure 9 B) shows strong antioxidant activity since it contains both 
phenolic hydroxyl groups as well as a β-diketone moiety, and in this respect it 
resembles with the well-known antioxidant of plant origin, viz. Curcumin [104] (Figure 9 
A). 
                     
                                         A                                                                   B 
 
Figure 9: Chemical structure of (A) Curcumin and (B) Garcinol 
 
Anti-oxidant properties of garcinol were confirmed in a recent study analyzing the 
effects of polyisoprenylated benzophenones on lipid and protein oxidation in vitro. 
Oxidative/ nitrative protein damage in human blood platelets and plasma was induced 
on treatment with peroxynitrite and the beneficial antioxidant properties of garcinol on 
lipid peroxidation was analyzed by levels of thiobarbituric acid reactive species 
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(TBARS). Role of garcinol as a protecting factor against diseases associated with 
oxidative stress is possible [105]. 
EGR-1, a transcription factor for Early Growth Response, autoregulates its 
activation and is a key vascular phenotypic switch modulated by phosphorylation and 
acetylation of Histone H3. In this study they used garcinol as a histone H3 
acetyltransferase inhibitor which inhibited IL-1beta-inducible EGR-1 transcription [106]. 
Garcinol turned out to be more potent than resveratrol as a bactericidal agent 
against H. pylori. Also, this study proved equivalent or better bactericidal activity of 
garcinol compared to clarithromycin, a standard drug against H. pylori at 6 and 12 h 
incubation, indicating a potential role for this antioxidant in treatment for H. pylori 
infection[107]. 
Garcinol showed antitumor activity against human leukemia HL-60 cells more 
effectively than curcumin, which was used as a reference compound in these studies 
[104]. Garcinol-induced apoptosis was triggered by the release of cytochrome c into the 
cytosol, procaspase-9 processing, activation of caspase-3 and caspase-2, degradation 
of PARP, and DNA fragmentation caused by the caspase-activated deoxyribonuclease 
through the digestion of DFF-45. The induction of apoptosis by garcinol was proven to 
be a pivotal mechanism for its cancer chemopreventive action in human leukemia cells.  
Anti-inflammatory and anti-cancer properties of garcinol in intestinal cancer cells 
was evaluated and compared to its oxidative derivatives. Garcinol was found to be more 
effective in inhibiting growth of intestinal cancer cell growth than that of normal 
immortalized cells. However, it should be pointed out that at low concentrations garcinol 
can stimulate cell growth [108]. In yet another study evaluating the anti-cancer 
properties of garcinol in colon cancer cells confirmed that garcinol reduced cell invasion 
and survival through the inhibition of focal adhesion kinase, MMP
signaling [109, 110].  
A recent study explaining the anti
suggested the involvement of TRAIL mediated apoptosis through upregulation of death 
receptors along with downregulation of antiapoptotic proteins
anticancer properties of garcinol in br
induction of apoptosis via activation
modulated by downregulation of NF
garcinol for the treatment of gastrointestinal ailments are known.
Figure 10: Known therapeutic 
 
In another study, the mechanistic role of garcinol in preventing aberrant crypt foci 
was evaluated [113]. Garcinol could suppress O (2) (
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expression of iNOS and COX-2 proteins. These findings support possible 
chemopreventive ability of garcinol, through induction of liver GST and QR, inhibition of 
O (2) (-) and NO generation and/or suppression of iNOS and COX-2 expression, on 
colon tumorigenesis.  
The effect of dietary feeding of garcinol on oral cancers was evaluated in a study 
by [114]. Dietary garcinol significantly reduced the incidence and multiplicity of tongue 
neoplasms and/or preneoplasms as compared to the control diet. Also, the COX-2 
expression in the tongue lesions was suppressed by feeding with garcinol. The potent 
anticancer properties of garcinol in oral cancers were suggested. 
Thus, current literature provides evidence for the potential of garcinol as a 
chemopreventive agent in carcinogenesis. Additionally, feeding garcinol-containing diets 
does not cause retardation of body weight gain and pathological alterations in liver and 
other organs including kidney, lung, heart, and esophagus, which is indicative of the low 
toxicity of the compound, which is a very attractive feature of any anti-cancer agent. 
However, the precise role of garcinol against pancreatic cancer remains unknown. 
31 
 
 
Overall hypothesis 
 
Pancreatic cancer is the fourth major cause of cancer related deaths in the 
United States in both men and women. It often escapes early diagnosis due to 
lack of explicit symptoms and early metastasis. Current treatment modalities 
include surgery, radiotherapy and chemotherapy. Gemcitabine remains the 
standard chemotherapeutic agent for treatment of PaCa. However, there is only a 
marginal survival advantage with multiple side effects and drug resistance. Thus, 
it is important to elucidate the molecular mechanisms involved in cancer and 
design alternative therapeutic strategies with better outcomes. Bioactive 
components from food have been traditionally used for medicinal purposes and it 
would be interesting to test these components in combination with standard 
chemotherapeutic agents for PaCa therapy.  
 
Garcinol, the bioactive agent from the rind of fruiting bodies of 
Mangosteen, is structurally similar to the known anti-cancer agent curcumin.  
Anti-inflammatory and anti-carcinogenic properties of garcinol have been 
recently recognized in oral, tongue, breast, skin and colon cancers. It would be 
interesting to analyze the anti- proliferative properties of garcinol individually and 
in combination with standard chemotherapeutic agent gemcitabine in PaCa cells.  
 
Also there is an obvious need to discover unique therapeutic markers and 
molecular signatures to combat pancreatic cancer. Evidence suggests that 
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expression patterns of miRNAs are a richer source of diagnostic tumor profiling 
as compared to messenger mRNA expressions. MiRNA are tissue specific and 
can target multiple genes and thus have important regulatory functions in 
carcinogenesis. 
 
The hypothesis for this study is that garcinol as a single agent or in 
combination with gemcitabine will prove to be an effectual therapeutic agent in 
human pancreatic cancer cells.  
         
In order to test the hypothesis, the following specific aims were proposed: 
 
Specific Aim 1: To evaluate the anti-proliferative properties of garcinol in PaCa cells 
Specific Aim 2: To evaluate the combined effect of Garcinol with (A) Curcumin or (B) 
Gemcitabine against PaCa cells. 
Specific Aim 3: To identify the alterations in microRNA expression profile in PaCa cells 
on treatment with garcinol and/or gemcitabine. 
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CHAPTER TWO 
METHOD 
Media and Chemicals 
 The established human pancreatic cancer cell lines BxPC-3 and Panc-1, and 
non-cancerous NIH3T3 were obtained from American Type Culture Collection 
(Manassas, VA, USA). NIH3T3 cells are mouse fibroblast cells developed by NIH and 3 
day transfer of 3 x 10^5 cells is the normal passage time for this cell line. The cell lines 
were maintained in continuous exponential growth by twice a week passage in RPMI-
1640 medium (Cellgro Manassas, VA; BxPC-3 cells) and Dulbecco modified Eagle’s 
medium (DMEM, Cellgro Manassas, VA; Panc-1 cells) respectively and supplemented 
with 10% fetal bovine serum, 4mM glutamine, sodium pyruvate, 100 units/ml penicillin 
and 10 mg/ml streptomycin in a humidified incubator containing 5% CO2 in air at 37°C 
for a maximum of 72 hours before each experiment. Each cell line was split regularly 
before attaining 70-80% confluence. 
 Antibodies were obtained from the following commercial sources: caspase-3 was 
purchased from Cell Signaling (Beverly, MA, USA); XIAP, cIAP from R&D Systems 
(Minneapolis, MN, USA), anti-Bcl-xL antibody from Trevigen Inc(Gaithersburg, MD, 
USA); anti-PARP antibody was from Biomol Research (Plymouth, PA, USA) and anti-β-
actin antibody was from Sigma Chemical Co. (St. Louis, MO, USA). Garcinol (Biomol 
International, USA) and Curcumin (Sigma Aldrich, USA) were reconstituted in DMSO to 
make 20 mM stock solution. This stock was stored at -20°C wrapped in aluminum foil to 
prevent dimer formation. The stock was diluted in DMEM to produce to concentrations 
to be tested. 
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Cell proliferation 
 Both PaCa cells were harvested using 0.025% trypsin at specific time points (24, 
48, 72 hr) after different concentrations of garcinol treatment (0-40 µM) and proliferation 
was inferred by counting the cells with a haemocytometer under microscope using 
Trypan Blue (Sigma Chemical Co.,St. Louis, MO,USA). Trypan Blue staining facilitates 
the visualization of cell morphology. Viable cells cannot take up the dye due to intact 
membrane whereas the non-viable cells get stained since the dye is permeable through 
damaged membrane, hence the proportion of viable cells in a population can be 
estimated.  Proliferation was expressed as number of cells counted for each treatment 
group relative to the cell number in absence of garcinol (untreated, control cells). 
 
Cell Viability 
 For cell viability assay, cells were seeded at a density of 3x103 cells/well in a 96 
well micro-titer culture plate. After overnight incubation the medium was removed and 
replaced with fresh medium containing different concentrations of garcinol (0-40 µM) 
alone or in combination with curcumin (0-50 µM) or gemcitabine (0-1 µM). After
 
specific 
time points (24, 48 and 72 hrs), 20µl of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) solution was 
added to each well and incubated further for one hour at room temperature. Color 
development due to reduction of tetrazolium in MTS to formazan is directly proportional 
to the number of living cells. This was measured spectrophotometrically at 595nm on a 
plate reader (BIO-TEK Instruments) and KC4 software was used for quantification. Cell 
proliferation was quantified as per the manufacturer’s protocol (Promega, USA). 
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 Cell viability has been expressed as a percentage, for each treatment group 
relative to control in absence of garcinol. The MTS assay calculates the % of live cells 
using the following equation: (sample - blank)/ (control - blank). The blank well contains 
only the MTS solution and is subtracted out in order to remove background absorbance. 
The control wells contain untreated cells, while the sample wells represent the treat 
cells. To monitor the effects of concurrent or sequential drug exposure the data 
obtained from the KC4 analysis was further subjected to analysis by Calcusyn (Biosoft 
®) software to predict additive, synergistic, or antagonistic effects. 
 
Quantification of Apoptosis 
 Apoptosis is characterized by membrane blebbing, condensation of cytoplasm 
and the activation of endogenous endonucleases. This leads to internucleosomal 
cleavage of DNA and the generation of mono- and oligonucleosomes, which are tightly 
complexed with histones. The DNA contained in these nucleosomes is protected from 
cleavage since it is tightly bound to the histones. The quantitative detection of these 
histone-associated DNA fragments in mono- and oligonucleosomes are a marker for 
apoptotic cells. 
 The Cell Apoptosis ELISA Detection Kit (Roche, Palo Alto, CA) was used to 
detect apoptosis according to manufacturer’s protocol. Briefly, after 48 hrs treatment of 
BxPC-3 and Panc-1 cells with different concentrations of garcinol (0-40 µM) alone or in 
combination with curcumin (0-50 µM) or gemcitabine (0-1 µM), the cytoplasmic 
histone/DNA fragments from cells were extracted and bound to immobilized anti-histone 
antibody as per the manufacturer’s protocol. Subsequently, a peroxidase-conjugated 
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anti-DNA antibody was used for the detection of immobilized histone/DNA fragments. 
After addition of the peroxidase substrate, the absorbance by the samples was 
determined at 405nm with an ULTRA Multifunctional Microplate Reader (BIO-TEK 
Instruments). 
 
Morphological changes 
DAPI (diamidino-2-phenylindole) is a blue fluorescent probe that fluoresces 
brightly when it is selectively bound to the minor groove of double stranded DNA where 
its fluorescence is approximately 20-fold greater than in the unbound state [115]. 
Morphological changes characteristic of apoptosis were determined by DAPI staining as 
per manufacture’s protocol (Invitrogen, USA).  
 Briefly 5x103 cells were seeded into 6 well culture plates containing 1-2 ml 
medium. After 24-36 hrs, garcinol (0-40 µM) alone or in combination with curcumin (0-50 
µM) or gemcitabine (0-1 µM), was added and incubated for another 48hrs. Cells were 
harvested by trypsinization, washed with PBS and subsequently incubated for 30 minutes 
with DAPI at room temperature in dark for 30 minutes. Prior to microscopic analysis the 
cells were stained with Prolong Gold Antifade reagent and visualized under Fluorescence 
Microscope (Nikon Eclipsia, 80i) with an Excitation maximum at 358 nm and an Emission 
maximum at 461 nm). 
 
Cell Cycle Analysis 
 After seeding cells in 6 well microplates, the cells were synchronized in the G1 
phase of cell cycle by serum starvation for 24 hours [116, 117]. Thereafter, the cells 
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resumed cell cycle in media containing serum and garcinol (0-40 µM). After treatment 
with garcinol the cells were collected by trypsinization, washed in cold PBS and fixed in 
450 µl ice-cold methanol by incubation for 1 h at 4°C. The cells were then centrifuged at  
1100 rpm, the pellet resuspended in 500 µl of PBS, incubated with RNase (20 µg/ml, final 
concentration) for 30 min at 37°C, stained with  propidium iodide (50 µg/ml, final 
concentration) for 1 h, and analyzed using FACScan flow cytometer (Becton Dickinson, 
USA). 
 
Caspase Activity 
 Caspase are a family of enzymes essential in cells for apoptosis. Caspase-3 and 
9 activities play a very important role in executing the process of apoptosis. Cell death 
was measured in whole-cell lysates prepared from samples treated with garcinol (0-40 
µM) alone or in combination with curcumin (0-50 µM) or gemcitabine (0-1 µM), using 
commercially available assay kit (R&D Assay System, Minneapolis, MN) according to 
manufacturer’s instruction. Briefly, for both the assays cells were treated with garcinol 
and cell pellets were collected by scarping the attached cells using extraction buffer and 
diluted using the calibrator diluents provided with the kit. Sample or standard were 
added to the plate, covered and incubated at room temperature for two hours. After a 
series of washing with wash buffers provided, samples were incubated with Caspase 
3/9 conjugates followed by 30 minute incubation in dark with the substrate solution. The 
reaction was stopped using stop solution and plates were mixed by gentle tapping. 
Optical density was determined using a microplate reader at 450 nm with wavelength 
correction set at 540nm. 
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Wound healing Assay 
 Cells were cultured in 35 mM culture dishes and maintained till 90% confluence 
was achieved. Using a sterile pipette tip, a scratch was made on the dish creating a 
wound through the cells. Microphotographic images were captured at the beginning and 
at regular intervals during cell migration till the wound closed in the control cells. The 
images were compared to determine the migration rate of the cells. 
 
Angiogenic factor Analysis 
 VEGF, MMP-9, IL-8 and PGE2 activity were measured in conditioned media 
collected from 1 x 106 cells treated with garcinol (0-40 µM) alone or in combination with 
gemcitabine (0-1 µM),  using a commercially available assay kit (R & D Assay System, 
Minneapolis, MN) according to manufacturer’s instruction. Briefly, cell culture 
supernates were collected and particulates were removed by centrifugation. Samples 
were stored at < -20° C until further use. 
VEGF, IL-8 and PGE2: Each well was soaked with the assay diluent followed by 
addition of standard, control or sample solution and incubated for 2 hours at room 
temperature. After a series of washing steps, the conjugate solution was added to each 
well, covered and incubated at room temperature for two hours. This was followed by 
addition of substrate solution and stop solution and incubation. The plate was read at 
450nm using a correction wavelength of 570 nm with the help of a microplate reader. 
MMP-9: Each well was soaked with the assay diluent followed by addition of standard, 
control or sample solution and incubated for 2 hours at room temperature on a 
horizontal orbital microplate shaker set at 500 ± 50 rpm. Following a series of washing 
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steps, p-aminophenylmercuric acetate (APMA) solution was added and plates were 
incubated for 2 hours at 37° C in a humidified envir onment. This step causes the 
activation of any potentially active form of MMP-9 in the sample. Substrate solution was 
added and the plate was incubated for 17 - 20 hours at 37° C in a dark, humidified 
environment. The relative fluorescence units (RFU) of each well was determined using 
a fluorescence plate reader set with the following parameters: excitation wavelength set 
to 320 nm or 340 nm and emission wavelength set to 405 nm; endpoint mode; 1 x 20 
mS integration time; plate speed = 6. 
 
Protein extraction and Western blot analysis 
 The pancreatic cancer cells- BxPC-3 and Panc-1 were plated in 100mm dish and 
allowed to attach for 36 hours. Garcinol (0-40 µM) alone or in combination with curcumin 
(0-50 µM) or gemcitabine (0-1 µM), was directly added to cell cultures at the indicated 
concentrations and incubated for 48 hrs. Control cells were incubated in the medium with 
equivalent concentration of DMSO. After the incubation period, the cells were harvested 
in PBS. Cellular lysates were prepared by suspending the cells in 200µl of lysis buffer 
(150mM NaCl, 1mM EGTA, 0.1% Triton X-100; 0.1mM sodium orthovanadate, 1mM 
phenylmethylsulfonyl fluoride and 2µg/ml leupeptin, 2µg/ml aprotinin). The cells were 
disrupted by sonication and extracted at 4°C for 30 minutes at maximal microfuge speed 
to remove debris. Cytosolic and Nuclear extracts were prepared using the Cytosolic and 
Nuclear extraction kit as per the manufacturer’s protocol (Pierce Biotechnology, USA). 
 For Western blot analysis, each extract prepared was used for preparation of 
loading sample equivalent to 35-50µg total protein and was separated on SDS-PAGE, 
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electro-transferred onto nitrocellulose membranes. The membrane was soaked in 5% 
milk solution for blocking at 4C on a slow speed overnight. After several washes, the 
membrane was soaked in primary antibody solution prepared in 5% BSA for 2-3 hrs. 
Depending on the protein in question, the antibody dilutions were done ranging from 
1:500 to 1: 2000. The membrane was washed and soaked in secondary antibody solution 
prepared in 5% milk solution with dilution of 1:5000. The membrane was washed several 
times to avoid background intensities. Detection of specific proteins (PARP, X-IAP, cIAP 
Pan, Bcl-xL) was carried out with an enhanced chemiluminescence Western blotting kit 
according to manufacturer’s instructions (Pierce Biotechnology, USA). 
 
Electrophoretic Mobility Shift Assay 
 The pancreatic cancer cells- BxPC-3 and Panc-1 were plated in 100mm dish and 
allowed to attach for 36 hours. Garcinol (0-40 µM) alone or in combination with curcumin 
(0-50 µM) or gemcitabine (0-1 µM), was directly added to cell cultures at the indicated 
concentrations and incubated for 48 or 72 hrs. Nuclear extracts were prepared according 
to the method described by Chaturvedi et al [118]. Briefly, the cells were washed with cold 
PBS and suspended in 0.15 ml of lysis buffer [10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF, 2 µg /ml leupeptin, 2µg /ml aprotinin, 
and 0.5 mg/ml benzamidine]. The cells were allowed to swell on ice for 20 min and then 
4.8 µl of 10 % Nonidet P-40 was added. The tubes were vortexed for a few seconds and 
centrifuged. The nuclear pellet was resuspended in nuclear extraction buffer [20mM 
HEPES  (pH 7.9), 0.4M NaCl, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.5mM PMSF, 2 
µg/ml leupeptin, 2 µg/ml aprotinin, and 0.5 mg/ml benzamidine] and incubated on ice. The 
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tubes were then centrifuged for 5 min in a microfuge at 4°C, and the supernatant (nuclear 
extract) was collected in a cold eppendorf tube and stored at –70°C for later use. The 
protein content was measured by BCA method. EMSA was performed by incubating 10µg 
of nuclear extract with IRDyeTM–700 labeled NF-κB oligonucleotide. The incubation 
mixture included 2 µg of poly (dI-dC) in a binding buffer. The DNA-protein complex 
formed was separated from free oligonucleotide on 8.0% native polyacralyamide gel 
using buffer containing 50mM Tris, 200mM glycine, pH 8.5, and 1mM EDTA, and then 
visualized by Odyssey Infrared Imaging System using Odyssey Software Release 1.1. 
 
Clonogenic Assay 
 To test the proliferation and differentiation of cells treated with garcinol, 
gemcitabine, or the combination, Panc-1 cells were plated (50,000 – 100,000 per well) 
in a six well plate and incubated overnight at 37°C. After 72-h exposure to 10 µM /L 
garcinol and 100nM gemcitabine, and the combination of the two, the cells were 
trypsinized, and the viable cells were counted (trypan blue exclusion) and plated in 100 
mm Petri dishes in a range of 100 to 1,000 cells to determine the plating efficiency as 
well as assess the effects of treatment on clonogenic survival. Based on the plating 
efficiency, 500 cells were then incubated for 10 to 12 days at 37°C in a 5% CO2/ 5% 
O2/ 90% N2 incubator. The colonies were stained with 2% crystal violet solution and 
counted. The surviving fraction was normalized to untreated control cells with respect to 
clonogenic efficiency [119]. 
42 
 
 
Cell Adhesion Assay 
 96 well plate was coated with Laminin-1 (10 µg/ml) at 4 degrees C overnight. 
After two washes with washing buffer (0.1% BSA in DMEM medium), the plate was 
blocked with 0.5% BSA in DMEM medium and kept in an incubator at 37 degrees C for 
1 hr. Wash with washing buffer and chill on ice. Add 50µl of garcinol (0-40 µM) and/or 
gemcitabine (0-1 µM) treated cells (4x105 cells/ ml) to each well and incubate in an 
incubator at 37 degrees C for 30 minutes. Shake the plate at 2000 rpm for 15 sec and 
wash with washing buffer thrice before fixing it with 4% paraformaldehyde. Incubate at 
room temperature for 15 minutes. Wash with washing buffer and stain for 10 minutes 
with crystal violet stain. Wash with water and drain off all the water to get dry plates. 
Incubate the plate with 2% SDS for 30 minutes and read at 550 nm [120]. 
 
Analysis of Cytotoxic Synergy 
Cells were plated as described above and allowed to attach overnight. The 
culture medium was replaced with fresh medium containing garcinol and gemcitabine or 
curcumin, individually and in combination in different ratios (Table 1) and the effect on 
cell growth was examined by the MTS assay method as described above. 
43 
 
 
Table 1: Treatment concentration for Synergy Analysis 
 
Treatment Ratio Garcinol (µM) Gemcitabine (nM) 
100:1 10 100 
 5 50 
 2.5 25 
50:1 5 100 
 2.5 50 
 1.25 25 
200:1 20 100 
 10 50 
 5 25 
 
Treatment Ratio Garcinol / Curcumin (µM) Curcumin / Garcinol (µM) 
1:2.5 4 10 
 2 5 
 1 2.5 
1:5 4 20 
 2 10 
 1 5 
1:10 2 20 
 1 10 
 0.5 5 
 
Data obtained was analyzed using the Calcusyn (Biosoft ®) software program, 
which utilizes the T.C. Chou method of determining synergy and antagonism. The 
combination index was determined at various toxicity levels for each cell line and at 
each drug ratio. For each ratio, three different concentration combinations were tested. 
The median-effect equation and combination index analysis was used to calculate the 
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interaction between treatment modalities. The combination index values (CI) for 
effective dose (ED50) at which 50% cells were viable was evaluated. This analysis 
determines if the effect is antagonistic, additive or synergistic. The analysis is termed 
median effect analysis and used extensively in biological systems [121, 122]. 
The mathematical equation of the median-effect equation is: fa/fu+ (D/Dm)m , 
where fa is the fraction affected by dose, fu is the fraction unaffected by the dose, D is 
the drug dosage, Dm is the dosage of the drug required to inhibit the growth of 50% of 
the cells and is determined from the x-intercept, and m is the coefficient signifying the 
sigmoidicity of the dose-effect curve. The logarithmic form of the median-effect equation 
was used to linearize the dose-response curves, and can be plotted to generate the 
median-effect plot. Log (D) plotted vs. log (fa/fu), the x-intercept obtained is log (Dm), 
from which the IC50 can be evaluated and the slope is the m value. The m and the Dm 
values obtained thereafter can be used to calculate the effective dose for any effect 
level [123].  
The combination index (CI) is used to determine synergism or antagonism. The 
equation is based on the multiple-drug effect equation. A CI value of one indicates that 
the effect of one drug is additive to the second, a CI value of greater than one indicates 
antagonism between the two drugs, and a CI value of less than one indicates synergism 
between the drugs (Table 2). The equation used to calculate CI is as follows: (D)1/(Dx)1 
+ (D)2/(Dx)2 + α (D)1(D)2/(Dx)1(Dx)2, where (Dx)1 and (Dx)2 are the doses for x% inhibition 
by drug 1 and drug 2 alone [121]. These values are obtained from the median-effect 
equation. (D)1 and (D)2 are the doses in combination that inhibit cell growth by x%. A 
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more detailed description of degrees of synergism and antagonism is listed in the table 
6.1 adapted from Chou and Hayball (1996). 
 
Table 2: Combination Index Values (CI) 
 
Range of Combination Index Values 
 
Description of Effect 
 
< 0.1 
 
Very strong synergism 
0.10 – 0.30 
 
Strong synergism 
0.30 – 0.70 Synergism 
 
0.70 – 0.85 Moderate synergism 
 
0.85 – 0.90 Slight synergism 
 
0.90 – 1.10 
 
Nearly additive 
1.10 – 1.45 Moderate antagonism 
 
1.45 – 3.30 Antagonism 
 
3.30 – 10 Strong antagonism 
 
> 10 Very strong antagonism 
 
 
RNA Isolation 
 Total RNA isolation was done using the miRNA mini easy kit from Qiagen 
(Valencia, CA, USA). Briefly, PaCa cells were treated with different 10µM garcinol and 
100nM gemcitabine individually and in combination for 36 hour. Cells were directly 
detached from the plate using lysis reagent, disrupted and homogenized by vortexing on 
full speed for one minute. Homogenate was incubated at room temperature for five 
minutes after which, chloroform was added and shaken vigorously to induce phase 
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separation. After leaving the samples at room temperature for two minutes, the samples 
are cold centrifuged for 15 minutes at 12,000 x g. Upper aqueous phase with the RNA is 
collected and 100% ethanol is added before passing it through the RNeasy mini columns 
and centrifuged. A series of buffers are added to isolate pure RNA from the column. 
Lastly, RNA is dissolved in RNase free water and stored frozen till use. Purity of RNA was 
checked by determining the 260/280 ratio. 
 
MicroRNA Microarray and Profiling 
Isolated total RNA samples were shipped on dry ice to LC Sciences (Houston, 
TX, USA) for microRNA enrichment and profiling using the microarray analysis. Dual 
chip analysis was done using Cy3 and Cy5 dye. For miRNA Human chip, five or more 
redundant regions are included. Each region further comprises a miRNA probe region, 
which detects miRNA transcripts listed in Sanger miRBase Release 7.1. Multiple control 
probes are included in each chip. The control probes are used for quality controls of 
chip production, sample labeling and assay conditions. From Cy3 and Cy5 images one 
may directly read miRNA profiles and from Ratio images one may get a quick sense of 
differential expressions between the corresponding samples [124]. Mature miRNAs and 
miRNA*s are sorted separately according to differential ratios. The ratio values are 
presented in log2 scale for quick and easy assessing differential direction as well as 
magnitude. A positive log2 value indicates an up regulation and a negative log2 value 
indicates a down regulation. One can easily convert a log2 value into a arithmetic ratio 
on a calculator by typing in 2^ (value). The signal values are derived by background 
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subtraction and normalization. Blank spaces represent signal values below detection 
level.  
A transcript to be listed as detectable must meet at least two conditions: signal 
intensity higher than 3× (background standard deviation) and spot CV < 0.5. CV is 
calculated by (standard deviation)/ (signal intensity). When repeating probes are 
present on an array, a transcript is listed as detectable only if the signals from at least 
50% of the repeating probes are above detection level. Signals are listed in median 
signal values of repeating probes of p-value < 0.01. During data process, “bad spots” 
that have signal values deviated more than 50% of average values of repeating spots 
and/or spot CV larger than 0.5 are discarded [125]. 
The images are displayed in pseudo colors so as to expand visual dynamic 
range. In the Cy3 and Cy5 intensity images, as signal intensity increases from 1 to 
65,535 the corresponding color changes from blue to green, to yellow, and to red. In the 
Cy3/Cy5 ratio image, when Cy3 level is higher than Cy5 level the color is green; when 
Cy3 level is equal to Cy5 level the color is yellow; and when Cy5 level is higher than 
Cy3 level the color is red. Multiple control probes are included on the microarrays for 
assessing various chip and assay qualities such as uniformity and specificity. Chips 
were scanned and the data was normalized. The t tests were done and the predicting 
target genes for various miRNAs were analyzed. 
 
MiRNA Real Time Reverse Transcription – Polymerase Chain Reaction (qRT-PCR) 
To verify the alterations in the expression of specific miRNAs that were found to 
be altered in miRNA microarray analysis, we chose representative miRNA (miR - 21, 
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miR -495, miR - 638, miR - 605 and miR – 196a) with varying expression profiles for 
real-time miRNA reverse transcription PCR (RT-PCR) analysis using TaqMan 
MicroRNA Assay kit (Applied Biosystems) following the manufacturer’s protocol. Briefly, 
Reverse Transcription master mix was prepared by adding 100mM dNTP mix, Reverse 
Transcriptase, 10x RT buffer, RNase inhibitor and nuclease free water. Each 15µl 
reaction consists of 7µl of Mastermix prepared above, 3µl respective primer and 5µl 
total RNA sample (5ng/15µl reaction). The thermocycler was programmed as follows: 
 
Step Type Time(Minutes) Temperature (C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
 
RT-PCRs were then carried out in a total of 25µl reaction mixture. Each tube 
composition was 1.66 µl RT product, 1.25 µl  20x TaqMan miRNA Assay mix, 12.5 µl of 
2x TaqMan Universal PCR Master Mix and 9.59 µl distilled water. The Smart Cycler II 
was programed as follows: 
 
Step Type Time Temperature (C) 
Initiation 10 Minutes 95 
40 Cycles 
(each cycle) 
15 Sec 
1 Minute 
95 
60 
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Statistical analysis 
 All the experiments were done in triplicate for each of the observations. Each of the 
data represents the mean ± SD from three separate experiments. To analyze the 
statistical significance of the differences found in the data, Analysis of Variance (ANOVA) 
was done. Statistical significance was assumed at p<0.05.  
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CHAPTER THREE 
RESULTS 
Specific Aim 1: To evaluate the anti-proliferative properties of garcinol in PaCa cells 
Human pancreatic cancer cell lines- Panc-1 and BxPC-3 were evaluated for 
putative therapeutic effect of garcinol from multiple viewpoints including its efficacy to 
potentiate loss of viable tumor cells, apoptosis stimulation, cell cycle arrest and further 
evaluate known cellular and molecular targets involved in the execution of these effects. 
Results obtained are described below. 
 
Effect of garcinol on PaCa cell proliferative status and viability - To evaluate 
the effect of garcinol on viability of PaCa cells in vitro, cells were cultured in 10% FBS 
containing medium for 24, 48 and 72 hrs with increasing concentrations of garcinol (0-
40µM). As noted in Figure 11A in PaCa cell lines, garcinol suppressed cell proliferation 
(as inferred from trypan blue exclusion assay), and significantly reduced the percentage 
of metabolically viable cells (as inferred by MTS relative to vehicle control) in a dose 
and time responsive manner (Figure 12). Inhibition of proliferation and < 50% loss of cell 
viability was evident with 20µM garcinol concentration in BxPC-3 cells. In contrast, in 
Panc-1 cells 10µM of garcinol at 72 hrs, caused <50% loss of viable cells (p < 0.01). 
The % cell viability observed at 72hrs with 10, 20, 30 and 40µM of garcinol in BxPc3 
cells were 55, 45, 30 and 20 % relative to control while in Panc-1 the figure tended to 
40, 35, 20 and 10 % respectively (relative to untreated control). Further, the phenotypic 
alterations following treatment showing loss of viable cells are depicted in Figure 11B. 
Taken together these results suggest that garcinol is an effective inhibitor of PaCa cell 
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viability and interferes with cell proliferation irrespective of their molecular genetic make-
up. However, BxPC-3 cells harboring wild type K-ras oncogene and mutated p53 was 
relatively more resistant to the effect of garcinol as compared to Panc-1 cells with 
mutant K-Ras and mutated p53. Further, to exclude the possibility of adverse effect of 
garcinol on normal epithelial cells, similar experiment was performed using MTS assay 
in immortalized mouse fibroblast NIH3T3 cells. The effect of garcinol was negligible at 
equivalent concentrations of this compound in these cells relative to PaCa cells (Figure 
12C)
 A BxPC-3   
 
 
B                        BxPC-3  
       
Figure 11: Effect of garcinol on PaCa cell p
A: Garcinol inhibited cell proliferation
by trypan blue exclusion assay 
pictures depicting dose dependent 
hour treatment with garcinol in both BxPC
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Figure 12: Dose and time response of g
Garcinol significantly inhibited metabolically viable cells in a dose and time responsive manner 
as inferred by MTS assay in human 
attained at ~15µM garcinol treatment in BxPC
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Garcinol induces apoptotic effects in PaCa cells - To investigate whether the 
loss of cell viability by garcinol treatment could in part be due to induction of apoptosis, 
we evaluated apoptosis based on criterion such as assessing nuclear morphological 
changes by DAPI staining, ELISA- Histone DNA analysis and additionally examining the 
extent of sub-G1 DNA by flow cytometry of fixed cells. As shown in Figure 13A, a 
significant increase in apoptotic cells was observed with increase in concentration of 
garcinol. This closely parallels to the loss of cell viability by garcinol treatment (48h) in 
both BxPC-3 and Panc-1 cells. Complimenting these findings, cells harboring abnormal 
nuclear morphology, typical of apoptosis such as apoptotic body formation, membrane 
blebbing, cell shrinkage, reduction in cell number, and nuclear condensation was scored 
under fluorescence microscopy in at least 500 garcinol treated PaCa cells after DAPI 
staining (Figure 13B). The observed morphological changes correlated well with Histone 
DNA ELISA findings following garcinol treatment in dose responsive manner in both cell 
lines investigated.  
A                 BxPC-3       
B BxPC-3  
  
Figure 13: Apoptosis inducing effect of g
A: Significant induction in apoptotic cells as demonstrated by enrichment of oligosomes and 
nucleosomes in the cytosol on undergoing apoptosis
analysis on BxPC-3 and Panc-1 cells
density values and enrichment factor was calculated by subtracting background 
0.05, ** p < 0.01 relative to control)
nuclear morphology, apoptotic body formation, reduction in cell number, all typical of apoptosis 
was scored in both PaCa cell lines, BxPC
garcinol treated cells using DAPI staining.
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Effect of garcinol on disruption of cell cycle in PaCa cells- The effect of 
garcinol treatment on cell cycle progression in PaCa cultured for 24 hrs was investigated 
by flow cytometry. Herein, again we noticed a relatively higher percentage of Panc-1 cells 
(0.3% vs. 36% cells at 0 and 40µM concentrations garcinol, respectively) being killed by 
garcinol compared to BxPC-3 cells (2% vs. 10% cells at 0 and 40µM concentrations of 
garcinol, respectively) as seen in Figure 14, 15 and Table 3. The effect was dose 
dependent. Cumulatively, these results indicate that PaCa cells undergo apoptosis 
following garcinol treatment, and a good correlation exists between apoptosis, loss of cell 
viability and reduced proliferation of cells. 
Garcinol treatment also resulted in a significant dose-dependent increase of cell 
population in the G0-G1 phase of the cell cycle in BxPC-3 cells (18% vs 65% cells at 0 vs 
40µM garcinol concentration, Figure 14A and B, Figure 15A and Table-3) and in Panc-1 
cells (31% vs 58% cells at 0 vs 40µM garcinol concentrations respectively, Figure 14A 
and B, Figure 15B and Table-3). This increase in cell population in the G0-G1 phase was 
found to be associated with concomitant decrease in cell population in the S and G2-M 
phase compared to corresponding controls. Overall, these results support the notion that 
the observed decline in cell population by garcinol is due to cell cycle arrest in G0-G1 
phase of cell cycle and induction of apoptosis. 
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Figure 14:  Histograms on FACS analysis of PaCa cells 
 
Cell cycle analysis was performed on cells synchronized in G1 phase by serum starvation in A: 
untreated control cells B: 40µM garcinol treated PaCa cells, BxPC-3 and Panc-1. Cells were 
fixed using propidium iodide and analyzed using flow cytometry analysis. Percentage of cells in 
each phase of cell cycle was depicted using histograms. Garcinol treatment resulted in G1 
phase arrest with increased apoptosis in PaCa cells relative to untreated control, with more 
significant effect on Panc-1 cells compared to BxPC-3 cells. 
 
 
 
 
 
 
A 
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Figure 15:  Flow cytometric analysis of PaCa cells
 
Bar diagram depicting percentage
20 and 40 µM) garcinol as estimated by FACS analysis in both PaCa cell lines, BxPC
Panc-1. Significant dose dependent arrest in G1 phase along with reduction in percentage of 
cells in S and G2-M phase and increase in apoptosis was observed upon garcinol treatment. 
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Table 3: Flow cytometry analysis of PaCa cells on treatment with garcinol 
 
 
 % G0-G1  % S  % G2-M  % Apoptosis  
BxPC-3: Control  18.1 ± 0.4  66.3 ± 1.1 15.6 ± 1.6 2.2 ± 0.09 
20µM Garcinol 60.3 ± 1.4 24.2 ± 5.1 15.4 ± 2.0 5.0 ± 1.3 
40µM Garcinol  65.2 ± 0.2 22.1 ± 0.04 12.6 ± 0.3 14.1 ± 1.1 
 
Panc-1: Control  31.0 ± 1.3  45.8 ± 0.4  23.2 ± 0.9  1.1 ± 0.7  
20µM Garcinol 69.0 ± 2.0  14.5 ± 1.7  16.6 ± 3.2  3.7± 0.2  
40µM Garcinol  57.8 ± 1.6  30.2 ± 1.9  12.0 ± 1.0  34.3 ± 1.9  
 
 
The mean values (± SE) represent the percentage of cells in the indicated phase(s) of the cell 
cycle from atleast two independent experiments.  
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Garcinol inhibits apoptotic molecules in PaCa cells- The molecular 
mechanism by which garcinol induces apoptosis in PaCa cells were investigated. 
Caspases are important mediators of apoptotic stimuli and therefore, we determined the 
enzyme activity levels of caspase-3 and caspase-9 in BxPC-3 and Panc-1 cells treated 
with garcinol. As seen in Figures 16A and 16B, garcinol significantly (p < 0.05) increased 
caspase-3 and caspase-9 activity by ~ 2 - 3 folds.  
Caspases are sequentially activated by proteolytic processing of their inactive 
procaspase forms into two smaller units, which in turn leads to cleavage of key cellular 
proteins including DNA repair enzyme poly ADP-ribose polymerase (PARP). As shown 
under Figure 17A, the Western immunobloting indicate that garcinol treatment resulted in 
the cleavage of PARP and appearance of the 85kDa cleaved intermediate in a dose 
dependent manner in Panc-1 cells. These results suggest that garcinol induces apoptosis 
in PaCa cells that may be mediated, at least in part, by the mitochondrial pathway.  
Inhibitors of apoptosis proteins (IAP) are over-expressed in human PaCa and 
they are thought to antagonize cell death by interacting with and repressing caspases. 
We therefore assessed protein expression levels by Western immunobloting using total 
cellular protein extract from garcinol treated cells. Relative to control, XIAP and cIAP 
protein expression was down-regulated in cells in a dose dependent manner when 
exposed to garcinol for 48hrs (Figure 17A). This provides mechanistic evidence of 
promotion of apoptosis induction by garcinol treatment in PaCa cells.  
A    
  BxPC-3 
 
 
B    
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Figure 16: Induction
 
Garcinol significantly increased 
PaCa cell lines, BxPC-3 and Panc
activity was measured in garcinol treated whole cell extracts using colorimetric assay 
0.05, ** p < 0.01 relative to control
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Garcinol inhibits activation of NF-κB- As discussed in the introduction, 
constitutively active NF-κB in pancreatic tumors contributes to the survival of cells by 
inhibiting apoptosis. To investigate whether garcinol could abrogate constitutively 
expressed NF-κB, PaCa cells were treated with different concentrations of garcinol for 48 
hrs. As shown in Figure 17B, treatment with garcinol resulted in a concentration 
dependent downregulation of NF-κB DNA binding ability in both BxPC-3 and Panc-1 cells. 
These results are consistent with down-regulation of XIAP proteins because the latter are 
transcriptionally regulated by NF-κB.  
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Figure 17: Garcinol downregulates apoptotic pathways. 
 
A: Western immunoblot analysis to detect expression of apoptotic proteins on garcinol 
treatment. Relative to control, garcinol treatment downregulated protein expression of IAPs, 
XIAP and cIAP Pan in PaCa cells. Cleaved band of PARP was observed in Panc-1 cells upon 
treatment with garcinol in a dose responsive manner B: Downregulation of NF-κB DNA binding 
ability on garcinol treatment as demonstrated by EMSA in both PaCa cell lines, BxPC-3 and 
Panc-1 in a dose responsive manner.  
B 
A BxPC-3      Panc-1 
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Effects of garcinol on MMP-9, VEGF, IL-8 and cell invasion abilities- MMP-9, 
VEGF and IL-8 are pivotal molecules in angiogenesis, invasion and metastasis of cancer 
cells and hence, we investigated whether garcinol could inhibit these angiogenic 
molecules. After 48hrs treatment relative to control, 20µM garcinol reduced the basal 
MMP-9 activity (Figure 18A) by 72% and 88% in BxPC-3 and Panc-1 cells respectively.  
IL-8 production (Figure 18B) was suppressed by approximately 78% in BxPC-3 cells and 
by 84% in Panc-1 cells. VEGF levels (Figure 18C) were inhibited by approximately 90% 
of basal level in BxPC-3 and Panc-1 cells. Inhibition of these molecules suggests that 
garcinol may be a potent suppressor of tumor neovascularization. PGE2 plays a role in 
augmenting VEGF in human PaCa cells. BxPC-3 which has over expressed COX-2 
enzyme, revealed significant reduction (~40% and 65%) in PGE2 levels following garcinol 
treatment at 10 and 20 µM concentration respectively (p < 0.01; Figure 19A). 
We therefore, examined, using in vitro wound healing assay, cell migration by 
creating scratch wounds in confluent monolayers of PaCa cells. After 24-hour incubation 
in 10% serum-containing media supplemented with 20µM garcinol concentration, the 
number of cells migrating from the wound edge decreased over time in both BxPC-3 and 
Panc-1 cells as illustrated in representative microphotographs (Figure 19B). Taken 
together, the above mentioned results indicate that garcinol is potentially effective in 
reducing angiogenesis and along with other invasive mediators- such as MMP-9, IL-8 and 
VEGF may lead to inhibition of tumor progression.   
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Figure 18: Effects of garcinol on angiogenic markers 
 
Effect of garcinol on angiogenic markers A: MMP-9 B: IL-8 and C: VEGF in PaCa cells, BxPC-3 
and Panc-1. Garcinol treatment suppressed MMP-9 activity, IL-8 levels and VEGF concentration 
in a dose responsive manner in 1x106 cells using quantikine and fluorokine assays (** p < 0.01 
relative to control).   
 A    
B 
Figure 19: Effects of garcinol on 
A: Effect of garcinol on PGE2 
enzymatic product, PGE2 in dose responsive manner on 48
Quantikine assay. (** p < 0.01 relative to control
estimated by in vitro wound healing assay.
After 24hr treatment with 20µM garcinol, number of cells migrating from woun
relative to control cells more apparently in Panc
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Figure 20: Summary of specific aim 1            
 
Garcinol downregulates NFκB in PaCa cells thereby influencing other downstream 
pathways involving angiogenesis, invasion, cell cycle and apoptotic modulators, thus 
inhibiting PaCa cell growth by inducing apoptosis and cell cycle arrest.  
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Specific Aim 2A: To evaluate the combined effect of Garcinol with Curcumin against 
PaCa cells. 
Dietary polyphenol curcumin has been extensively investigated as an anti-cancer 
agent and is currently undergoing several Phase-I, II and III clinical trials. This part of 
the study was designed to test the hypothesis that curcumin may synergistically interact 
with garcinol leading to therapeutic or chemoprotective advantage in PaCa. Results 
presented include evaluation of garcinol and curcumin as individual agents in human 
pancreatic cancer cell lines- Panc-1 and BxPC-3, and their combined effect compared 
for synergistic outcome.  
 
Effect of garcinol and curcumin on cell viability- PaCa cells, BxPC-3 and 
Panc-1 were tested for their effects on cell viability under the influence of curcumin and 
garcinol as single agent regimen. It was noted both agents under identical experimental 
conditions, significantly (p < 0.01) reduced cell viability in both cell lines in a dose 
dependent manner on 48 hrs treatment, but to different extents. Garcinol exhibited more 
potent effect than curcumin (IC 50 = ~7 µM) in Panc-1 cells, which was comparable to 
efficacy of curcumin in BxPC-3 cells (IC 50 = ~10 µM) as shown in Figure 21. Garcinol 
and curcumin hold some structural resemblance but our results suggest that their 
therapeutic mechanistic targets might be different. In BxPC-3 cells (Figure 21 A) IC50 
for garcinol treatment (upper panel) was approximately 12µM as compared to 10µM of 
curcumin (Figure 21 B). In contrast, in Panc-1 cells (Figure 21) IC50 values for garcinol 
(upper panel) and curcumin (lower panel) treatment were 7µM and 20µM respectively. 
We hypothesized these two agents in combination could be a better strategy for the 
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treatment of PaCa. We earlier mentioned no effect of garcinol on surrogate 
untransformed cells (NIH3T3). 
 
A BxPC-3            Panc-1 
               
B            
               
 
Figure 21: Effect of curcumin and garcinol on PaCa cell viability 
 
Percentage of metabolically viable cells was reduced in a dose responsive manner on 48hr 
treatment with A: garcinol or B: curcumin on both PaCa cell lines, BxPC-3 and Panc-1 as 
analyzed using MTS assay. * p < 0.05, ** p < 0.01 relative to control.  
  
70 
 
 
Garcinol and curcumin induce apoptosis in PaCa cells- To confirm 
apoptosis, we performed Histone DNA ELISA assay and observed that both curcumin 
and garcinol were effective in inducing apoptosis in a dose dependent manner (Figure 
22). Relative to control the enrichment factor in BxPC-3 cells was found enhanced by ~ 
7, 10 and14 folds with garcinol at 10, 20 and 40µM concentrations respectively. The fold 
increase in histone enrichment factor on treatment with 15, 30 and 50µM curcumin 
concentrations was 10, 12 and 17 folds respectively. A similar trend was seen for Panc-
1 cells. The results obtained corroborate well with morphological changes associated 
with apoptosis such as formation of apoptotic bodies and reduction in cell numbers 
evaluated using DAPI stain in both Panc-1 and BxPC-3 cells (Figure 23).  
Based on the objective outlined under Aim-2, we sought to investigate the effect 
of curcumin and garcinol in combination in induction of apoptosis. Figure 24 depicts the 
changes seen when curcumin and garcinol were combined in different ratios of 1:4 and 
1:10 (2.5µM curcumin/garcinol: 10µM garcinol/curcumin; and   2µM curcumin/garcinol: 
20µM garcinol/ curcumin) of respective concentrations. As noted under Figure 24 in 
both cell lines the combination regimen had pronounced effect on induction of apoptosis 
compared to respective individual agent treatment supporting our hypothesis that 
curcumin and garcinol have synergistic effect in reducing cell viability and augmenting 
apoptosis.  
A     BxPC-3  
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Figure 22: Induc
 
A: garcinol or B: curcumin treated cytosolic extracts were used 
apoptosis in PaCa cells, BxPC-
Results demonstrate a significant
treatment with either agent. Enrichment factor was measured using subtraction of background 
signal. * p < 0.05, ** p < 0.01 relative to control
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Figure 23: Apoptotic morphological changes on treatment with curcumin and garcinol 
 
Apoptotic morphological changes such as abnormal nuclear morphology, reduction in cell 
number with apoptotic body formation and cell shrinkage was observed in a dose responsive 
manner on 48 hour treatment with curcumin or garcinol. BxPC-3 and Panc-1 cells were fixed 
with DAPI stain and visualized using fluorescence microscopy with an excitation maximum at 
358nm and emission maximum at 461nm.    
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Figure 24: Apoptotic m
 
Apoptotic morphological changes
number with apoptotic body formation and cell shrinkage was observed in a dose responsive 
manner on 48 hour treatment with curcumin and
and Panc-1 cells were fixed with DAPI stain and visualized using fluorescence microscopy with 
an excitation maximum at 358nm and emission maximum at 461nm. 
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Garcinol and curcumin exhibit synergistic relation in PaCa therapy- To 
evaluate the extent of synergism, the combination effect of garcinol and curcumin (in 
variable ratios) was tested for cell viability. Cell viability was reduced significantly (p < 
0.01) in Panc-1 cells upon treatment and the loss of viable cells were more drastic in 
combinatorial regimen group compared to individual doses (Figure 25A). Using 
CalcuSyn software for Isobologram analysis, the combination index values (CI) for 
different ratios of treatment in Panc-1 cells was determined. 
 Table 4 and 5 depict the different CI values obtained upon treatment. CI = 1 
indicates additive effect, < 1 indicates synergistic effect and > 1 suggests antagonistic 
effect. The CI values for ED50 (Effective dose for 50 % inhibition) when curcumin and 
garcinol were administered in the ratios of 1:10, 1:5 and 1:2.5 were 0.201, 0.422 and 
0.659 respectively (Table 4). Three combinations were tested for each ratio. 
Furthermore, Dm defined as the median-effect dose or concentrations signifying 
the potency of the treatment were 26µM and 17.65µM for curcumin and garcinol, 
respectively. Dm is an important parameter which helps in establishing dose reduction 
which leads to lowered toxicity in the host, thus retaining overall therapeutic efficacy. It 
is usually represented in correlation with ED50 values. We observed that when Panc-1 
cells were treated with curcumin and garcinol, in the ratios of 1:10, 1:5 and 1:2.5 the Dm 
values were 4.57, 8.57 and 10.79 µM respectively. Based on the CI ED50 values and 
the Dm values one may conclude 2- to 5- fold lower concentration requirement in 
combination treatment than individual treatments in order to achieve similar effect.  
Similarly when the ratio of garcinol and curcumin were reversed (Table 5) and 
the cells were treated with 1:10, 1: 5 and 1: 2.5 of garcinol to curcumin, the CI values at 
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ED50 were 0.756, 0.747 and 0.921 respectively. The Dm values recorded for the same 
ratios were 1.25, 2.32 and 5.11 µM respectively.  
In related context, ‘m value’ is another parameter describing the sigmoidicity of 
the dose effect curve; m = 1, > 1, < 1 indicates hyperbolic, sigmoidal and negative 
sigmoidal shape respectively. It was noticed that the m value was > 1 in all our samples 
except when curcumin: garcinol were in the ratio of 1:10 suggesting sigmoidicity of the 
curve. Further, the linear correlation coefficient of the median effect plot is represented 
as’ r value’. An r value equal or close to 1 indicates perfect conformity of the data as 
was seen in our experimental results showing an r value close to 1 (0.97 – 1.00) in all 
our samples. The foregoing results clearly narrate that garcinol and curcumin have 
potent synergistic effect in reducing PaCa cell viability. 
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Figure 25: Cytotoxic synergy: curcumin and garcinol 
 
A: Combination effect of curcumin and garcinol on Panc-1 cell viability was determined using 
MTS assay. Combinatorial treatment significantly reduced cell viability more effectively than 
monotherapy on 48hr treatment. * p < 0.05, ** p < 0.01 relative to control. B: Isobologram 
analysis to evaluate the extent of synergism on combining curcumin and garcinol for therapeutic 
effect.  
77 
 
 
Table 4: Combination index values for curcumin- garcinol synergy 
 
Drug ED 50 ED 75 ED 90 Dm m r 
Curcumin N/A N/A N/A 26.00 1.60 0.99 
Garcinol N/A N/A N/A 17.65 2.27 0.99 
Curcumin: Garcinol 
1:10 
0.201 0.472 1.111 4.57 0.72 0.99 
Curcumin: Garcinol 
1:5 
0.422 0.633 0.957 8.47 1.05 1.00 
Curcumin: Garcinol 
1: 2.5 
0.659 1.087 1.812 10.79 0.98 0.99 
 
When ratio of garcinol concentration was higher in the combination than curcumin, the CI value 
at ED75 (Effective dose at which 75 % cells are non-viable) suggested a moderate to high 
synergism between the two agents under investigation. 
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Table 5: Combination index values for curcumin- garcinol synergy 
 
Drug ED 50 ED 75 ED 90 Dm m r 
Curcumin N/A N/A N/A 26.00 1.60 0.99 
Garcinol N/A N/A N/A 17.65 2.27 0.99 
Garcinol : Curcumin 
1: 10 
0.756 0.675 0.603 1.25 2.88 0.99 
Garcinol: Curcumin 
1:5 
0.747 0.853 0.978 2.32 1.72 1.00 
Garcinol : Curcumin 
1: 2.5 
0.921 1.415 2.188 5.11 1.15 0.97 
 
When ratio of curcumin concentration was higher in the combination than garcinol, the CI value 
at ED75 (Effective dose at which 75 % cells are non-viable) suggested a low to moderate 
synergism between the two agents under investigation.  
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Specific Aim 2B: To evaluate the combined effect of Garcinol with Gemcitabine against 
PaCa cells. 
As reported earlier the pyrimidine nucleoside analog-gemcitabine is the standard 
drug for treatment of PaCa, but conventional dosing with this drug at maximal tolerated 
dose cause adverse side effects and patients fail to respond adequately after multiple 
cycles of therapy due to the emergence of drug-resistance. Thus, we sought to examine 
the chemo-sensitization potential of garcinol in combination with gemcitabine to reduce 
viable tumor cells and induce apoptosis using low concentrations of gemcitabine.    
 
              Garcinol and gemcitabine inhibit cell viability and apoptosis- As shown in 
Figure 26A, gemcitabine inhibited cell viability in a dose dependent manner in the two 
investigated PaCa cell lines with more than 50% loss of cell viability with ~50nM 
gemcitabine in BxPC-3 cells and ~250nM in Panc-1 cells upon 72 hour treatment. This 
finding is in concordance with other studies reported in literature [126] and accordingly 
Panc-1 cells being classified as ‘gemcitabine resistant’ cells. To address the objective 
as outlined under Aim- 2B we used sub-optimal concentrations of gemcitabine for 
chemosensitization of PaCa cells for therapy. Thus, the efficacy was explored using 
combination comprising 3 different concentrations of garcinol (1, 2.5, and 5µM in BxPC3 
cells and 2.5, 5 and 10µM in Panc-1 cells) co-incubated with 2 different concentrations 
of gemcitabine (25 and 50nM in BxPC3 cells, whereas 50 and 100 nM concentration in 
Panc-1 cells) and the results are shown in Figure 26C. From the results presented, it is 
inferred that a significant loss of cell viability occurs when relatively low dose of 
gemcitabine is combined with garcinol relative to monotherapy. In BxPC-3 cells, the loss 
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of viable cells was ~75 % (10µM garcinol and 50nM gemcitabine) compared to ~50 % 
with 10µM of only garcinol and ~55 % with 50nM gemcitabine. A similar trend was also 
noticed in Panc-1 cells with only ~30 % of viable cells following combination treatment 
comprising 20µM garcinol and 100nM gemcitabine as compared to their respective 
individual treatments. These figures compare significantly less than single agent 
treatment for similar duration of time (p < 0.01).  
Further, to confirm that the loss in viability owes to cell death by apoptosis, 
quantification of Histone-DNA ELISA and alterations in cellular morphological features 
were evaluated as described previously. As depicted in Figure 27 A and B, following 
combinatorial regimen of garcinol and gemcitabine in both investigated cell lines, a 
significant increase in apoptotic cells along with morphological alterations closely 
mimicking the loss of viable cells is evident. This data attests chemosensitization 
potential of garcinol in PaCa therapy.  
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Figure 26: Effect of garcinol and gemcitabine on PaCa cell viability 
Significant dose dependent reduction in cell viability upon 72 hour treatment with A: 
gemcitabine. IC50 value in BxPC-3 cells was attained at 50nM concentration as compared to 
250nM in Panc-1 cells.  B: garcinol, IC50 value was attained at ~15µM treatment in BxPC-3 
cells compared to 10µM in Panc-1 cells and C: sub-optimal concentrations of gemcitabine were 
combined with three different concentrations of garcinol to achieve enhanced loss in cell 
viability.  ** p < 0.01 relative to control. 
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Figure 27: Apoptotic
 
Induction of apoptotic cells on treatment with garcinol and gemcitabine
combination was observed using 
gemcitabine was combined with ga
measured by estimation of enrichment of cytosolic nucleosomes. 
to control.  B: Apoptotic morphological changes 
were observed using DAPI stain
gemcitabine.  
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 Garcinol treatment enhances apoptosis by gemcitabine inducing caspase 
activity- To confirm sensitization and apoptosis by garcinol and gemcitabine treatment, 
we assessed caspase-3 and caspase-9 activity in the investigated cell lines- BxPC-3 
and Panc-1 cells (Figure 28A and B). Cells were exposed to garcinol and gemcitabine 
as depicted in figure 28, either as single agent or in combination for 48hrs. At end of 
incubation period cells were collected (including floating cells) and caspase activity was 
determined as per manufacture’s instruction. Data shows that while garcinol treatment 
at investigated dose do not cause a significant increase in caspase-3 and 9 relative to 
control, the combination regimen revealed significant increase in their activity being 
elevated more than one and half - two fold relative to control (p < 0.05; p < 0.01, Figure 
28).  
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Figure 28: Induction of caspase activity on treatment with garcinol and gemcitabine 
 
Colorimetric analysis for A: Caspase 3 and B: Caspase 9 activity in PaCa cells, BxPC-3 and 
Panc-1 cell line. Gemcitabine individually or in combination with garcinol depicted a significant 
increase in enzyme activity  . * p < 0.05, ** p < 0.01 relative to control.  
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Garcinol inhibits activation of NF-κB and down-regulates NF-κB activation 
stimulated by gemcitabine and augments apoptosis by gemcitabine - We 
previously mentioned that garcinol could downregulate constitutively expressed NF-κB 
in PaCa, cells (Figure 17B).and regulated many anti-apoptotic proteins. We therefore 
assessed NF-κB on treatment with garcinol. Experiments were performed exposing 
BxPC-3 cells and Panc-1 to 10µM garcinol and gemcitabine (25 or 100nM concentration 
respectively; Figure 29A) treatment for 72 hrs and thereafter prepared the nuclear 
extract as described under Materials and Methods section and subjected it to DNA 
binding assay by EMSA. It was concluded that 10µM garcinol treatment of cells could 
significantly reduce the NF-κB DNA binding activity in combination treatment (Figure 
29A). These results demonstrate that garcinol is effective in down-regulating NF-κB 
DNA binding activity in PaCa cells, but together in combination with gemcitabine could 
further downregulate NF-κB in PaCa cells, which is consistent with our hypothesis.  
 Mechanistically, to confirm chemosensitization effects of garcinol via induction of 
apoptosis, we assessed the alteration of key apoptotic (PARP cleavage) and anti-
apoptotic (Bcl-xL) protein molecules expression in Panc-1 cells by Western 
immunobloting (Figure 29B). Our data show that while treatment with garcinol or 
gemcitabine alone show no appearance of cleaved PARP; their combination showed 
strong cleaved PARP band indicative of apoptosis induction. Consistent with the results 
obtained with PARP cleavage, significant down-regulation of the anti-apoptotic Bcl-xL in 
the combination treatment group (Figure 29B) was also noted indicating that garcinol 
indeed sensitizes PaCa cells to the cytotoxic effect of gemcitabine.  
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Figure 29: Effect of garcinol and gemcitabine on NFκB levels and apoptotic markers 
 
A: Transcription factor NF-κB levels were analyzed in garcinol and gemcitabine treated nuclear 
extracts using EMSA analysis in PaCa cells, BxPC-3 and Panc-1. A down-regulation in NF-κB 
DNA binding ability was observed in combination treated cells relative to control. B: Western 
immunobloting to assess influence of garcinol and gemcitabine treatment in Panc-1 cells was 
done. Strong cleaved band of PARP was observed in combination treatment relative to 
individual treatments along with downregulation in expression of anti-apoptotic protein Bcl-xL. 
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Garcinol inhibits clonogenic survival of cells with gemcitabine - Based on 
our results showing apoptosis, the clonogenic survival of cells treated with garcinol was 
moderately reduced relative to control, while gemcitabine treatment lead to a significant 
decrease in clonogenic survival of Panc-1 cells. Most interestingly, the combination 
group showing more cytotoxicity resulted in fewer clones compared to control and single 
agent-treatment alone (p < 0.001; Figure 30A).  
Cell adhesion is a crucial step in cancer progression playing a pivotal role in 
recurrent, invasive and distant metastasis. Several cell adhesion molecules (CAM) 
regulate the entire process. We performed a quantitative analysis as described under 
methods to check for effect of garcinol and gemcitabine on cell adhesion ability. In 
BxPC-3 cells, cell adhesion reduced by half in combination (50nM gemcitabine and 5µM 
garcinol) treatment as compared to individual effect of 50nM gemcitabine (p < 0.01) 
(Figure 30B). Similar trend was observed in Panc-1 cells on treatment with 100nM 
gemcitabine and 10µM garcinol than respective individual treatments.   
A   Clonogenic Assay: Panc
          
 
B   Cell Adhesion Assay
 BxPC-3  
Figure 30: Action of garcinol 
A: Clonogenic assay in Panc-1 cells
cells were treated with garcinol alone or in combination with g
were formed in combination treatm
determined by one way ANOVA
adhesion using laminin coated plates. 
cell adhesion more potently than garcinol treatment.
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Effects of garcinol and gemcitabine on MMP-9, VEGF, IL-8 and PGE2 - As 
mentioned under Aim-1 of the dissertation, these are important molecules implicated in 
angiogenesis, invasion and metastasis of cancer cells and garcinol exhibited dose 
dependent effect in inhibition of these molecules (Figure 18 and 19) . We further 
investigated the potential of garcinol in chemosensitization reference to these molecules 
under the conditions of combination treatment using sub-optimal dose of gemcitabine. 
The experimental details have been described under Methods section. Results of this 
experiment indicate downregulation of these molecules in both the investigated cell lines 
by single agents; however the effect was significantly pronounced (p < 0.01) in each of 
the combination group which may have a profound impact in progression of PaCa tumor 
(Figure 31A-C). 
Additionally, PGE2 assay also done under the same experimental conditions and 
a similar trend was noted, being significantly reduced in the combination group (Figure 
32A). A qualitative wound healing assay (Figure 32B) was performed to test for individual 
effects of garcinol and gemcitabine on cell migration. We observed an expansion in the 
wound on treatment with either agent after 24 hour as compared to a closed wound in 
untreated control cells.  
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Figure 31: Downregulation of angiogenic markers 
Effect of garcinol and gemcitabine treatment on levels of angiogenic markers A: VEGF, B: 
MMP-9 activity and C: IL-8 in PaCa cells, BxPC-3 and Panc-1. 1x106 cells were treated with 
gemcitabine and/or garcinol for 48hr and supernate was collected and evaluated for various 
angiogenic markers using quantikine and fluorokine assay. Significant reduction in levels of 
angiogenic markers was observed in combination treatment relative to individual therapies. * p < 
0.05, ** p < 0.01 relative to control. 
 
A    
B
Figure 32: Effect of garcinol and gemcitabine on invasion and m
A: PGE2 concentration as determined 
cells was significantly down-regulated on single agent treatment but more effectively in 
combination dose. * p < 0.05, ** 
healing assay on treatment with garcinol and gemcitabine depicting the ability of these agents in 
restricting cell migration and proliferation upon treatment.
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Synergistic effect of garcinol and gemcitabine combination – The concept 
related to ‘synergistic interaction’ between garcinol and curcumin has been mentioned 
earlier. On similar platform, we evaluated the combination of garcinol and gemcitabine for 
chemosensitization of PaCa as described in the experimental setup under Methods. 
Based on cell viability data, the combination index values (CI), Dm, m and R values were 
obtained using different ratios of treatment with garcinol and gemcitabine in BxPC3 and 
Panc-1 cells (Figure 33A and Figure 34A) using CalcuSyn software and presented in 
Table-6 and 7. As depicted in Figures 33B and 34B, the CI values tend to be either 1 or < 
1 indicating a synergistic or additive effect of the combination. 
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Table 6: Cytotoxic synergy of garcinol and gemcitabine in BxPC-3 cells 
 
Drug ED 50 ED 75 ED 90 Dm m r 
Gemcitabine (Gz) N/A N/A N/A 9706.2 1.77 1.00 
Garcinol N/A N/A N/A 5624.1 1.35 1.00 
Garcinol: Gz 
50:1 
1.47 1.02 0.717 3209.3 2.72 1.00 
Garcinol: Gz 
100:1 
1.02 0.88 0.768 3659.2 1.87 1.00 
Garcinol: Gz 
200:1 
0.86 0.76 0.69 4499.7 1.86 1.00 
 
Combination index values on treatment with garcinol and gemcitabine in combination resulted in 
synergism (CI < 1) in higher ratios of 100:1 and 200:1 in BxPC-3 cell.   
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Figure 33: Cytotoxic synergy of garcinol and gemcitabine in BxPC-3 cells  
A: Combination effect of gemcitabine and garcinol on BxPC-3 cell viability was determined 
using MTS assay. Combinatorial treatment significantly reduced cell viability more effectively 
than monotherapy on 48hr treatment. * p < 0.05, ** p < 0.01 relative to control. B: Isobologram 
analysis to evaluate the extent of synergism on combining gemcitabine and garcinol for 
therapeutic effect.  
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Table 7: Cytotoxic synergy of garcinol and gemcitabine in Panc-1 cells 
 
Drug ED 50 ED 75 ED 90 Dm m r 
Gemcitabine (Gz) N/A N/A N/A 299.97 0.99 1.00 
Garcinol N/A N/A N/A 17585 1.11 1.00 
Garcinol: Gz 
50:1 
1.504 1.068 0.760 12175 1.55 0.99 
Garcinol: Gz 
100:1 
0.821 0.654 0.523 9104.5 1.37 1.00 
Garcinol: Gz 
200:1 
0.967 0.571 0.338 13158 2.26 1.00 
 
Isobologram analysis used to evaluate combination index values on treatment with garcinol and 
gemcitabine in combination resulted in synergism (CI < 1) in higher ratios of 100:1 and 200:1 in 
Panc-1 cells which are categorized as gemcitabine resistant phenotype. CI value suggests the 
potential of garcinol in sensitizing PaCa cells to the effect of gemcitabine.  
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Figure 34: Cytotoxic synergy of garcinol and gemcitabine in Panc-1 cells 
A: Combination effect of curcumin and garcinol on Panc-1 cell viability was determined using 
MTS assay. Combinatorial treatment significantly reduced cell viability more effectively than 
monotherapy on 48hr treatment. * p < 0.05, ** p < 0.01 relative to control. B: Isobologram 
analysis to evaluate the extent of synergism on combining curcumin and garcinol for therapeutic 
effect.  
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Figure 35: Summary of specific aim 2 
 
Carcinogenesis is a multi-step process. Normal cells exhibit a balance between cell 
division and cell death, when this equilibrium is disrupted, cells lose their ability to 
undergo apoptosis and continue to proliferate and grow. They start to invade and 
colonize in areas normally reserved for other cells. We observed the efficacy of garcinol 
in combination with gemcitabine to target molecules regulating multiple pathways in 
carcinogenesis. Dietary interactions of garcinol and curcumin proved to be synergistic in 
inhibiting cell viability in PaCa cells. The effect of this combination on other mechanistic 
pathways needs to be explored further.  
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Specific Aim 3: To identify the alterations in microRNA expression profile in PaCa cells 
on treatment with garcinol and/or gemcitabine. 
 MicroRNAs regulate gene expression at transriptional levels targeting multiple 
genes involved in carcinogenesis. The current aim was conducted to test the hypothesis 
that garcinol individually or in combination with gemcitabine will alter the miRNA 
expression in PaCa cells, downregulating oncogenes and upregulating apoptotic and 
tumor suppressor genes.  The resuts obtained are as discussed below.  
 
 Garcinol induces changes in miRNA expression profile on treatment- To 
evaluate the alterations in miRNA expression induced by garcinol, microRNA microarray 
analysis was done on 10µM garcinol treated Panc-1 cells and miRNA enrichment was 
done from total RNA. Using one way ANOVA, signal intensities between the two groups 
were analyzed for statistical significance. Comparison of signal intensity between Group 
1 (untreated control cells) vs. Group 2 (10µM garcinol treated cells) was made. Log2 
(G2/G1) represents the fold change in specific miRNA upon treatment (Table 8). On 
treatment with garcinol a downregulation in expression of miRNA – 21 (0.56 fold), - 495 
(1.14 fold), -494 (0.97 fold), -1977 (0.80 fold) was observed as compared to untreated 
control implying their oncogenic role in PaCa.  An upregulation in expression of miR – 
453 (4.69 fold), - 128 (1.82 fold), - 1280 (0.46 fold) – 720 (0.43 fold) compared to control 
suggest tumor suppressor activity of these miRNAs. During analysis, a systematic dye 
bias was found on probes for miR - 377 and was suggested to be excluded from further 
investigation.   
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Figure 36: Heat map of alterations in miRNA due to Control vs. Garcinol treatment 
Panc-1 cells were treated with 10µM garcinol and the miRNA profile was compared to untreated 
control cells (p < 0.01).  Those miRNAs that  were different between the two groups have been 
listed in table 8.  
 
Table 8: Alterations in miRNA profile in Control vs. Garcinol treatment 
 
100 
 
 
 Signal intensity comparisons between Group 1 (untreated control cells) vs. Group 
2 (100nM gemcitabine treated cells) was made. On treatment with gemcitabine a 
downregulation in expression of miRNA – 605 (1.46 fold) was observed as compared to 
untreated control implying their oncogenic role in PaCa.   
 
 
 
Figure 37: Heat map of alterations in miRNA due to Control vs. Gemcitabine treatment 
Panc-1 cells were treated with 100nM gemcitabine and the miRNA profile was compared to that 
of untreated control cells (p < 0.01). Signifiant changes between the two groups have been 
listed in Table 9. 
 
 
 
Table 9: Alterations in miRNA profile in Control vs. Gemcitabine treatment 
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 To evaluate the alterations in miRNA expression induced by combination 
treatment of 10µM garcinol and 100nM gemcitabine, microRNA microarray analysis was 
done on combination treated Panc-1 cells and miRNA enrichment was done from total 
RNA. A comparative analysis (Table 10) of signal intensities between Group 1 
(untreated control cells) vs. Group 2 (combination treated cells) revealed a 
downregulation in expression of miRNA – 196a (0.82 fold), - 495 (1.26 fold), -1914 (1.85 
fold), -605 (2.42 fold) and -483-3p (1.06) as compared to untreated control implying their 
oncogenic role in PaCa.  An upregulation in expression of miR – 638 (0.65 fold), - 720 
(0.41 fold), - 453(4.78 fold) and – 663 (0.92 fold) compared to control suggest tumor 
suppressor activity of these miRNAs. During analysis, a systematic dye bias was found 
on probes for miR - 377 and was suggested to be excluded from further investigation.   
 Based on the fold change in miRNA expression between the two groups (Figure 
39), we extended our analysis on six miRNAs miR - 21, -196a, - 495, - 453, - 638 and – 
605.  
 
Figure 38: Heat map of miRNA due to Control vs. Combination treatment 
Panc-1 cells were treated with combination of 100nM gemcitabine and 10µM garcinol. The 
miRNA profile was compared to that of untreated control cells. (p < 0.01). Signifiant changes 
between the two groups have been listed below. 
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Table 10: Alterations in miRNA profile in Control vs. Combination treatment 
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Figure 39: Alterations in miRNAs between Control vs. Combination treatment. 
 
 A bar diagram depicting the fold change in miRNA expression profile of untreated control cells 
and combination treated cells.  
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 Data obtained by microRNA microarray analysis was validated using quantitative 
Real Time PCR analysis (RT-PCR). 5ng/ reaction tube of total RNA was used for 
preparation of assay reaction and the experiment was performed as per the 
manufacturer’s instructions. RNU6B was used as a standard and a 2^ (-delta delta Ct) 
value was evaluated for comparative analysis of specific miRNA under investigation 
(Figure 40). We further performed a statistical analysis to check for correlation in 
expression between the two methods (Table 11).  
 An R2 value of 0.73, 0.90, 0.81, 0.78, 0.74 and 0.92 was obtained for expression 
of miR – 196a, - 495, - 21, - 453, - 638 and – 605 respectively suggesting average to 
good correlation between the two analytical methods. TargetScan 5 software analysis 
revealed the potential targets for each of these miRNAs from the current database. This 
database was built using the Wilcoxon test, to identify those miRNAs which are present 
significantly more often in set of changed genes compared to background of unchanged 
genes. A p-value is calculated signifying that the changed and unchanged sets were 
produced by the same distribution and the differences between them were due to 
chance alone. An equivalent negative natural logarithm of the p-value was used as a 
more intuitive measure for analysis. Table 12- 17 list the potential target pathways, their 
corresponding genes, statistical significance and KEGG pathway ID for the respective 
miRNAs.  
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Figure 40: Validation of miRNA profile by Real Time RT-PCR analysis 
Comparative expression of miRNA levels in Panc-1 cells was detected using microarray 
profiling and validated using Taqman RT-PCR method. * p < 0.05, ** p<0.01 relative to control. 
R2 values are listed in Table 11.  
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Table 11: Correlation coefficient for qRT-PCR and microarray analysis 
 
miRNA R2 value 
hsa-miR-196a 0.7308                                
hsa-miR-495 0.9008                                   
hsa-miR-21 0.8182              
hsa-miR-453 0.7760                                
hsa-miR-638 0.7361                                   
hsa-miR-605 0.9165 
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Table 12: Signaling pathways targeted by hsa-miR-21 
 
Targeted Pathway Gene Name -ln (p-value) KEGG Pathway ID 
Cytokine-cytokine 
receptor 
interaction 
CCL1, CNTFR, LIFR, CCL22, CCL20, 
FASLG, CCR7, ACVR2A, IL12A, 
TGFBR2, BMPR2 
9.77 hsa04060 
TGF-beta signaling 
pathway 
SMAD7, ACVR2A, TGFBR2, 
ACVR1C, BMPR2, PITX2 9.5 hsa04350 
MAPK signaling 
pathway 
MAP2K3, NTF3, MAP3K1, FASLG, 
FGF1, DUSP8, PPP3CA, TGFBR2, 
ACVR1C, RPS6KA3 
7.73 hsa04010 
Pancreatic cancer CDK6, PIK3R1, TGFBR2, ACVR1C 4.54 hsa05212 
Jak-STAT 
signaling pathway 
CNTFR, LIFR, PIK3R1, IL12A, 
SPRY1, SPRY2 4.39 hsa04630 
Apoptosis BCL2, FASLG, PIK3R1, PPP3CA 3.82 hsa04210 
VEGF signaling 
pathway PIK3R1, PPP3CA, NFAT5 2.23 hsa04370 
Notch signaling 
pathway JAG1, RBPJ 1.62 hsa04330 
Focal adhesion BCL2, VCL, ITGB8, PIK3R1, COL4A1 1.56 hsa04510 
mTOR signaling 
pathway PIK3R1, RPS6KA3 1.25 hsa04150 
 
Ref: DNA Intelligent Analysis Database.  
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Table 13: Signaling pathways targeted by hsa-miR-196a 
 
Targeted Pathway Gene Name -ln (p-value) KEGG Pathway ID 
ECM-receptor 
interaction 
COL1A1, COL3A1, COL5A2, 
COL1A2 10.59 hsa04512 
Focal adhesion PDGFRA, COL1A1, COL3A1, COL5A2, COL1A2, CCND2 9.73 hsa04510 
Cell 
Communication 
COL1A1, COL3A1, COL5A2, 
COL1A2 5.59 hsa01430 
Jak-STAT 
signaling pathway SOCS4, OSMR, CCND2, RNF31 4.83 hsa04630 
Gap junction CSDE1, PDGFRA, ADCY9 4.35 hsa04540 
MAPK signaling 
pathway MAP4K3, CSDE1, PDGFRA, MAX 2.19 hsa04010 
mTOR signaling 
pathway TSC1, IGF1 2.11 hsa04150 
ErbB signaling 
pathway CDKN1B, CSDE1 1.59 hsa04012 
TGF-beta signaling 
pathway CHRD, SMAD6 1.53 hsa04350 
Regulation of actin 
cytoskeleton CSDE1, PDGFRA, PPP1R12B 1.28 hsa04810 
Cell cycle CDKN1B, CCND2 1.05 hsa04110 
 
Ref: DNA Intelligent Analysis Database.  
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Table 14: Signaling pathways targeted by hsa-miR- 495 
 
Targeted 
Pathway Gene Name -ln (p-value) 
KEGG 
Pathway ID 
Insulin 
signaling 
pathway 
PPARGC1A, IRS2, PRKY, KRAS, RHEB, 
CBL, PIK3R1, SOS1, PRKX, IRS1, PRKCI, 
RHOQ, PPP1CC, ELK1, PRKAB2, MAPK10, 
TRIP10, SHC4, PRKACB, PIK3R3, AKT3, 
RAF1, EIF4E 
14.81 hsa04910 
Wnt signaling 
pathway 
PRKY, FZD5, TBL1X, DKK1, CAMK2G, 
PRKX, APC, CREBBP, SIAH1, FRAT2, 
PPP3CA, NLK, CCND2, NFAT5, TCF7L1, 
MAPK10, PRKACB, JUN, FZD6, CTBP2, 
FZD10, PPP3CB 
11.7 hsa04310 
MAPK 
signaling 
pathway 
MAP4K4, HSPA2, PDGFRA, TGFBR1, 
MAP3K1, KRAS, RRAS2, STK4, SOS1, 
FGF2, CDC42, RAP1B, NLK, NF1, FGF5, 
PTPRR, ELK1, EGF, TGFB2, MAP3K5, 
MAPK10, JUN, AKT3, RAF1, 
11.08 hsa04010 
Pancreatic 
cancer 
TGFBR1, KRAS, CDK6, PIK3R1, CDC42, 
ACVR1B, JAK1, EGF, TGFB2, MAPK10, 
PIK3R3, AKT3, RAF1 
8.19 hsa05212 
VEGF 
signaling 
pathway 
SH2D2A, KRAS, PIK3R1, KDR, CDC42, 
PPP3CA, PTK2, NFAT5, PIK3R3, AKT3, 
RAF1, PPP3CB 
7.03 hsa04370 
mTOR 
signaling 
pathway 
RHEB, PIK3R1, IGF1, PIK3R3, AKT3, EIF4E 7 hsa04150 
Cell cycle 
DBF4, CDKN2C, YWHAB, SMC1A, 
ANAPC1, CDK6, HDAC2, CDC25C, 
CREBBP, TGFB2 
5.1 hsa04110 
 
Ref: DNA Intelligent Analysis Database.  
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Table 15: Signaling pathways targeted by hsa-miR- 453 
 
Targeted Pathway Gene Name -ln (p-value) KEGG Pathway ID 
ErbB signaling pathway PAK2, PIK3R3, CAMK2B 9.14 hsa04012 
T cell receptor signaling 
pathway NFKBIB, PAK2, PIK3R3 8.91 hsa04660 
B cell receptor signaling 
pathway NFKBIB, PIK3R3 5.08 hsa04662 
Phenylalanine, tyrosine 
and tryptophan 
biosynthesis 
GOT2 4.5 hsa00400 
Regulation of actin 
cytoskeleton PAK2, SLC9A1, PIK3R3 3.28 hsa04810 
One carbon pool by folate SHMT1 2.79 hsa00670 
Wnt signaling pathway PRICKLE2, CAMK2B 1.74 hsa04310 
Focal adhesion PAK2, PIK3R3 1.13 hsa04510 
 
Ref: DNA Intelligent Analysis Database.  
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Table 16: Signaling pathways targeted by hsa-miR- 638 
 
Targeted Pathway Gene Name -ln(p-value) KEGG Pathway ID 
Adherens junction IGF1R, NLK, ACTN4, ACVR1C, SMAD4 10.21 hsa04520 
Wnt signaling 
pathway 
CSNK1A1L, NLK, CACYBP, FZD4, 
NFAT5, SMAD4 6.27 hsa04310 
Pancreatic cancer NFKB1, KRAS, CDK6, SMAD4 6.05 hsa05212 
Hedgehog 
signaling pathway GLI3, CSNK1A1L, PTCH1 4.13 hsa04340 
MAPK signaling 
pathway 
RPS6KA2, NFKB1, KRAS, BDNF, 
NR4A1, NLK, ACVR1C 3.87 hsa04010 
ErbB signaling 
pathway KRAS, CBL, ABL2 2.08 hsa04012 
Cell cycle CDC27, SMC1A, SMAD4 1.32 hsa04110 
 
Ref: DNA Intelligent Analysis Database.  
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Table 17: Signaling pathways targeted by hsa-miR- 605 
 
Targeted Pathway Gene Name -ln(p-value) KEGG Pathway ID 
ABC transporters - General ABCC9 7 hsa02010 
Glycolysis / Gluconeogenesis PGK1 2.6 hsa00010 
Purine metabolism AK2 2.36 hsa00230 
ErbB signaling pathway PAK2 1.86 hsa04012 
Ubiquitin mediated proteolysis BRCA1 1.25 hsa04120 
 
Ref: DNA Intelligent Analysis Database.  
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MicroRNA is tissue specific in carcinogenesis. The alterations in expression profile of 
six miRNAs on exposure to 
495, - 196a are oncogenic miRNA. The signal intensity reduced significantly on 
treatment with garcinol or gemcitabine as a single agent or in combination. MiR
expressions increased only on 
gemcitabine, suggesting garcinol specific effect. MiR
deregulated in gastric cancers. A significant up regulation in miR
noted on treatment with garci
clear. Garcinol treatment increased the signal intensity to almost double whereas the 
signal reduced to less than half on treatment with gemcitabine alone or in combination. 
Further analysis is needed to confirm the expression analysis of this miRNA.
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41: Summary of specific aim 3 
garcinol and/or gemcitabine was evaluated. 
treatment with garcinol alone or in combination with 
-638, a tumor suppressor, 
-638 expression was 
nol and/or gemcitabine. The role of miR-605 is not very 
 
MiRNA-21, -
-453 
is often 
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CHAPTER FOUR 
 
DISCUSSION 
 
Despite advancements in modern medicine, pancreatic cancer continues to be a 
major public health problem in US and many parts of the world with dismal prognosis. 
According to American Cancer Society and NCI/NIH statistics, 43,140 new cases will be 
detected in 2010 and 36,800 deaths will be reported due to this disease due to futility of 
present treatment protocols and strategies in successfully treating this disease. This is 
in part, due to inability of clinicians to address the highly chemoresistant nature of these 
neoplasms because of which majority of the patients relapse despite continued therapy. 
Numerous clinical trials have been tried using various drugs or combinations involving 
chemo- and radiotherapy/ immunotherapy/ targeted therapy in PaCa, but unfortunately 
none of these therapeutic alternatives have reasonably increased medium survival of 
patients diagnosed with PaCa.  
Several epidemiological studies, overwhelming data demonstrate an inverse 
relationship between intake of dietary chemopreventive agents as a promising strategy 
for reducing human cancer risk. Of late, there has been a great deal of interest in 
developing chemotherapeutic trials that are based on natural dietary agents. A few 
previous studies have reported garcinol- the bioactive component derived from Garcinia 
indica to inhibit tumor growth in animal models [111, 114, 127]. In the present study we 
investigated putative therapeutic potential of garcinol in PaCa cells. This is the first 
study reporting the therapeutic properties of garcinol on PaCa encompassing 
multidirectional aspects - as single agent, combination with other known dietary 
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chemopreventive agent (curcumin), chemosensitization efficacy with gemcitabine, and 
its influence on microRNA expression profile. Unfortunately, bioavailability of this 
compound in either healthy human subjects or rodent models has not yet been 
explored. However, based on subjective indirect evidence, garcinol is speculated to 
reach systemic circulation but detail pharmacokinetics and pharmaco-dynamics of this 
compound needs to be analyzed.  
Over the years we have realized that no single agent by itself can eliminate or 
treat cancer, instead combination of different naturally occurring phytochemicals can 
afford protection. However, therapeutic efficacy of interactions amongst various dietary 
agents needs further in-depth analysis. Data thus far, suggests that increased 
consumption of curcumin isolated from Curcuma longa (a.k.a. Turmeric), contributes to 
lowering risk of cancer in Asian (Indian) populations compared to industrialized western 
nations. Additionally, based on our limited preliminary findings, garcinol appears to 
exhibit promising therapeutic efficacy in PaCa cells. Epidemiological studies report that 
Asian (Indian) populations consume turmeric and kokum as a component of their diet 
regularly. This lead to our hypothesis that interactions between two bio-active 
components- turmeric (Curcumin) and kokum (Garcinol) can influence PaCa cell growth 
and proliferation. Based on this rationale, we evaluated whether the combination of 
these two bio-active components have any additive, synergistic or antagonistic effect on 
human pancreatic cancer cells in overcoming intrinsic tumor cell resistance to apoptosis 
and inhibition of angiogenesis in PaCa cells.  
PaCa results from the successive accumulation of gene mutations and is a multi-
faceted process. Thus, targeting multiple metabolic pathways involved at different 
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stages by using combinatorial approaches could either delay or halt progression of 
disease. Gemcitabine is an FDA approved standard cytotoxic chemotherapeutic agent 
used for the treatment of PaCa. One reason for the limited success of gemcitabine in 
treatment of PaCa is due to development of resistance due to over expression of 
proliferation linked signaling molecules like EGFR, NF-κB, Akt, STAT, etc. or anti-
apoptotic molecules such as survivin, Bcl-2, Bcl-XL XIAP’s etc. and mutations in several 
oncogenes like K-ras, p53, p16 and DPC4. Thus, finding an effective therapeutic 
strategy for PaCa is the primary need of the situation. An ideal therapy would be the 
one that would target multiple signaling pathways at low doses and be able to 
discriminate between normal cells and cancer cells, specifically targeting only the latter. 
We report feasibility of an alternate approach which was tested and found to be 
synergistically effective in improving overall therapeutic efficacy.  
As reported in literature more than 80% of pancreatic cancer patients present 
with unresectable, locally advanced or metastatic disease, with dismal prognosis of 
having not more than 6 months of median survival. Thus, in addition to novel 
therapeutic modalities and approaches there is also need to investigate therapeutic 
targets specific for this disease. This would be useful in designing efficient strategies for 
better survival and monitor clinical outcome in patients. In this context the role of 
microRNAs in carcinogenesis is emerging and it is now known that microRNAs control 
gene expression at the post transcriptional levels and are more informative than mRNA 
expression profiles for pathological evidence. Each miRNA can target approximately 
200 genes depending on their complementarity and thus can act as tumor suppressors 
or oncogenes. Therefore, in this study the microRNA profile of human PaCa cells 
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following treatment with gemcitabine and garcinol was pursued to gain better molecular 
insight for future implementation.  
In the current study, garcinol significantly inhibited PaCa cell viability and cell 
proliferation irrespective of their molecular genetic makeup as demonstrated by MTS 
assay and trypan blue exclusion method, respectively (Figure 11-12). The two PaCa cell 
lines used were Panc-1, which as mentioned earlier is a poorly differentiated PaCa cell 
line that possesses mutated K-ras as well as p53 mutation, and BxPC-3 cells which is a 
moderately differentiated cell line with wild type K-ras and point mutated p53. BxPC-3 
cells were found relatively more resistant to the effect of garcinol as compared to Panc-
1 cells (Figure 12). Since Panc-1 cells have been classed under category of 
‘Gemcitabine resistant’ the potential of garcinol in inhibiting cell viability and proliferation 
in these cells should not be under estimated. Moreover, based on our results garcinol 
treatment complied to induction of apoptosis and cell cycle arrest in G0-G1 phase 
(Figure 13-15); thus the ability of garcinol to induce apoptosis and halt cell division by 
cell arrest makes it a promising candidate for further investigations including phase-I 
clinical trial.  
To elucidate the mechanism involved in apoptosis, levels of various pro- and 
anti-apoptotic molecules which regulate cell death were analyzed. Among these, 
caspases are important mediators of apoptosis and are sequentially activated by 
proteolytic processing of their inactive procaspase forms into two smaller units, which in 
turn leads to cleavage of key cellular proteins including DNA repair enzyme poly ADP-
ribose polymerase (PARP). Caspase 9 belongs to the initiator Caspase tier and plays a 
crucial role in activating the effector Caspase 3 which ultimately induces apoptosis. 
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Caspases are known to be induced by various agents including phytochemicals and 
apoptotic stimuli; therefore we determined the invitro activities of caspase-3 and 
caspase-9 in both cell lines upon treatment. Colorimetric assay data revealed increasing 
activity of caspase-3 and caspase-9 in PaCa cells following garcinol treatment (Figure 
16). This was complimented by the presence of cleaved PARP band confirming 
apoptosis (Figure 17). In addition, several Inhibitor of Apoptotic Proteins (IAPs) such as 
XIAP, cIAP (Pan) that negatively regulate apoptosis were also investigated and found to 
be downregulated in dose responsive manner by garcinol treatment. Both these 
mechanisms need further analysis. The nuclear transcription factor- NF-κB is 
constitutively active in pancreatic tumors, and contributes to the survival of cells by 
inhibiting apoptosis, thus playing a central role in pathogenesis, progression, invasion 
and metastasis in PaCa. Analysis of this transcription factor in PaCa cells revealed its 
downregulation by garcinol in a dose responsive manner (Figure 17).  
NF- κB is believed to be a critical determinant of drug resistance in pancreatic 
and other cancers and inhibition of this nuclear factor sensitizes PaCa cells to 
chemotherapy induced apoptosis. NF- κB also targets proteasome inhibitors, as they 
normally prevent the degradation of IκB, thus blocking nuclear translocation of NFκB. 
Thus, inhibition of NF- κB by garcinol carries significant consequence in enhancing the 
sensitivity to cytotoxic drugs. This has been confirmed under another aim of this study. 
Angiogenesis, invasion and metastasis are the mechanisms by which cancer 
cells spread and strengthen their foundation. Pancreatic tumors are highly vascular and 
produce multiple pro-angiogenic factors and cytokines such as VEGF, MMP-9, and IL-8 
which help in invasion and progression of cancer cells. Epidemiological evidence shows 
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that over expression of VEGF and IL-8 in pancreatic cancer patients correlates with 
poor survival. Interleukins (IL-8) belongs to family of pro-inflammatory cytokines that 
assist in the process of invasion and angiogenesis. Mechanisms to block cytokines, 
exhibit a tumorostatic effect rather than a tumoricidal effect, hence their performance 
can be enhanced by using them for adjunct therapy with suitable drugs.  Hence, we 
investigated the fate of these angiogenic and metastatic markers on treatment with 
garcinol. We observed a significant dose dependent reduction in levels of VEGF, MMP-
9 and IL-8 (Figure 18). These findings supports the contention that garcinol may be a 
potent suppressor of tumor neovascularization and may predictively be effective in 
reducing angiogenesis and other invasive mediators leading to inhibition of tumor 
progression. 
 Also, Prostaglandin E2 (PGE2),which is the enzymatic product of COX-2 activity 
is commonly over expressed in pancreatic tumors and thought to be an important 
mediator of chemoresistance and therefore considered as promising chemotherapeutic 
target for the treatment of pancreatic cancer. Panc-1 cells have very low levels of COX-
2 expression as compared to BxPC-3 cells and thus we determined the effect of 
garcinol on PGE2levels in COX-2 overexpressing cell line BxPC-3 only. There was a 
significant reduction in PGE2 levels upon treatment with garcinol (Figure 19) It is well 
known that promoter sequence of COX-2 contains binding sites for NF-κB, which overall 
forms a very crucial network promoting the survival of tumor cells. Since we noticed a 
dose dependent decrease in levels of PGE2 and NF-κB, one may speculate that garcinol 
treatment would be effective in down regulating COX-2 enzyme by inhibiting NF-κB 
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activity. This mechanism needs further investigation along with analysis of upstream 
molecular events leading to downregulation of NF-κB by garcinol. 
Based on foregoing discussion and our initial conviction that garcinol may have 
therapeutic advantage, its effect in combination with another potent chemo dietary 
agent- curcumin was investigated (Figure 25). Appraisal of combination index values 
along with apoptosis induction by this combination proved to be synergistic / additive 
with greater inhibition of cell viability and induction of apoptosis through the upregulation 
of caspase activity. Other related parameters such as Dm, m and r values, the 
significance of which have been mentioned earlier, favors advantage of this combination 
in prospective future studies concerning therapy of PaCa relative to single agent and 
requires to be tested more rigorously in future. 
Another aspect under this study paradigm was to explore whether garcinol could 
be therapeutically combined with gemcitabine for the treatment of PaCa in addition to 
conventional therapeutics that have thus far shown limited benefit. Results presented 
conclude that garcinol is effective as a general inducer of apoptosis in PaCa cells by 
down-regulating anti-apoptotic proteins and stimulating caspase activity without any 
adverse effect on normal epithelial cells (NIH 3T3). The combination regimen also 
severely restricted the growth of clonogenic colonies compared to single therapy 
regimens.  Moreover, the transcription factor NF-κB as described earlier, is intimately 
involved with de novo and acquired chemoresistant phenotype of PaCa cells [38, 126, 
128]. Numerous studies also support that inactivation of NF-κB leads to sensitization of 
cancer cells to conventional therapeutics [129-133]. Zhang et al recently reported that 
IKK inhibitor could confer sensitivity to PaCa cells and xenograft tumors by blocking 
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events upstream of NF-κB pathway and thus in consequence also affect NF-κB 
downstream genes, that lead to enhanced effect on TNF-α in abrogating growth of 
tumor cells, activating apoptosis [134]. Our findings clearly demonstrate that garcinol in 
combination with gemcitabine interferes in synergistic loss of cell viability through the 
upregulation of apoptosis and downregulating NF-κB activation in both PaCa cell lines. 
Moreover, it is known that antiapoptotic Bcl-xL, regulated by NF-κB at the transcriptional 
level also contributes to PaCa chemo-resistance which can be suppressed by NF-κB 
inhibition. Moreover, VEGF, MMP-9 and PGE2 levels exhibited greater inhibition in the 
combination treatment group relative to single agent therapy (Figure 31). PGE2 being 
enzymatic product of COX-2 expression is elevated in pancreatic cancer tissues over 
normal controls, thereby increasing VEGF synthesis via EP2 receptor. We also report 
maximum inhibition of IL-8 in combinatorial treatments as compared to individual 
therapies (Figure 32). We thus conclude that adding garcinol to standard therapy for 
PaCa might be a viable and promising therapy to control invasion and spread of cancer 
cells.  Although search for the development of alternative gemcitabine schedules and 
chemotherapy combinations continues, the present findings support that garcinol is a 
novel agent that profoundly impacts chemosensitization of PaCa. 
As discussed earlier, pancreatic ductal adenocarcinoma has the poorest overall 
prognosis amongst gastrointestinal cancers due to its asymptomatic nature, thus limiting 
therapeutic options. Gemcitabine remains the standard care for PaCa patients today, 
however multiple side effects and development of chemoresistance is a major hurdle in 
developing successful strategy to handle this disease. Thus there is much room for 
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improvement in all aspects of treatment for PaCa. In this study we aimed to evaluate the 
potential microRNA targets of garcinol and gemcitabine for PaCa therapy. 
 The role of microRNAs in carcinogenesis has been recognized not too long ago. 
In the current study, total RNA isolation was performed on garcinol and/or gemcitabine 
treated Panc-1 cells. A quality check using the 260/280 ratio was done to determine the 
quality of isolation. The total RNA samples were enriched for microRNA, labeled and 
hybridized to a chip and cluster analysis was performed at a separate facility by a 
technical expert. Only miRNAs with significant signal intensity over background and 
those that showed a differential intensity between groups were used for further analysis. 
Untreated control group was compared with either 10µM garcinol or 100nM gemcitabine 
or the combination treatment. Based on the fold changes in the respective groups, six 
microRNAs were used for further analysis to identify the target pathways of respective 
treatments.  
As part of the constant efforts that are being made to identify microRNAs specific 
for PaCa we evaluated the targeted pathways of six microRNAs under the influence of 
treatment. MiR-21 is involved in inducing gemcitabine resistance in PaCa cells [135]. A 
downregulation in signal intensity of miR-21 by 32%, 1% and 22% was noted on 
treatment with garcinol, gemcitabine and combination respectively compared to 
untreated control. A significant (p-value: 2.93E-03) reduction miRNA-21 signal intensity 
on treatment with garcinol alone as compared to untreated control cells was observed 
(Figure 36, Table 8). Role of miRNA-21 in chemoresistance was clearly demonstrated 
on treatment with gemcitabine alone and in combination with garcinol. Using 
TargetScan5 software analysis, we listed a few common targets for miRNA-21 (Table 
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12). Among these are, cytokine receptor, TGF-β signaling, MAPK signaling, Jak-STAT 
signaling, apoptosis, VEGF, Notch, mTOR signaling and Focal adhesion pathways. 
Recent study provided evidence of positive correlation between miRNA-21 and mRNA 
expression of angiogenic factors such as VEGF, MMP-9 and others [88]. This 
information is parallel to our findings. Thus treatment with garcinol can be a potent 
strategy to inhibit miR-21 and overcome the effect of cytotoxic chemoresistance in 
PaCa cells.  
Another oncogenic miRNA, miR-196a was evaluated and downregulated by 
garcinol (25%), gemcitabine (33%), and combinatorial (43%) treatment compared to 
control. A gradual reduction in signal was observed on treatment with single agent; 
however the combination treatment (p-value: 5.75E-03) reduced miR-196a signal 
intensity by almost half suggesting a potent therapeutic effect on PaCa cells (Figure 38, 
Table 10).. Molecular targets of miRNA-196a as determined by TargetScan5 software 
are known to be associated with ECM receptor interactions, focal adhesion pathway, 
cell communication, Jak-STAT signaling, mTOR, actin cytoskeleton regulation and cell 
cycle regulation (Table 13). Yekta and colleagues first described miR-196a-directed 
cleavage of specific homebox genes (HoxB8, HoxC8, HoxD8 and HoxA7) in mouse 
embryos and mammalian cells thus promoting tumor progression by cell detachment 
and tumor cell dissemination in vitro via activation of Akt pathway [136]. A recent study 
describing the role of miR-196a in colorectal cancer suggested that miRNA was mainly 
involved in enhanced cell detachment, migration, invasion and chemosensitivity towards 
platin drugs [137]. Also, studies using miRNA chip analyses in pancreatic cancer found 
that 75% of tumors expressed high levels of miR-196a [91, 138]. Overall downregulation 
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of this miRNA can be a promising strategy for therapy, since it influences major 
pathways of carcinogenesis. 
90% of PaCa cases have K-ras mutation [139]. The role of miR-495 on treatment 
with both agents was evaluated in PaCa cells since it is known to be overexpressed 
(>10 folds) in K-ras positive tumors [140]. Signal intensity of miR-495 was 
downregulated by 55%, 15% and 59% on treatment with garcinol, gemcitabine and 
combination respectively. Garcinol alone or in combination with gemcitabine showed 
significant (p-value: 1.45E-04) reduction (Figure 36, Table 8).. Target analysis using 
TargetScan5 software revealed its association with pathways involving Insulin signaling, 
mTOR, VEGF, cell cycle, Wnt and MAPK molecules (Table 14). Since K-ras mutation is 
commonly associated with PaCa, targeting miR-495 by garcinol alone or in combination 
would be a key step in designing efficient therapeutics.  
Certain microRNAs are known to regulate carcinogenesis as a tumor suppressor. 
MiRNA-638 was downregulated in gastric cancers suggesting a tumor suppressor 
activity [141]. We observed an upregulation in signal intensity of miR-638 on treatment 
as compared to untreated PaCa cells. Garcinol upregulated miR-638 signal intensity by 
31%, gemcitabine by 7% and combination by 57% relative to control cells. Our results 
clearly suggest that garcinol in combination with gemcitabine could induce the tumor 
suppressor activity of miR-638 more potently (p-value: 5.14E-03) than either agent 
alone (Figure 38, Table 10). Also, gemcitabine by itself was not very efficient in 
upregulating miR-638 levels, but a synergistic effect on combining with garcinol is 
possible as suggested by the signal intensity values. Known targets of miR-638 are 
molecules of glucose metabolism, EGFR pathway, purine metabolism and ubiquitin 
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mediated proteolytic activities (Table 16). It would be interesting to explore the exact 
mechanism by which garcinol mediates the induction of this miRNA.  
The exact function of miRNA – 605 and – 453 in gastrointestinal cancers is not 
well documented. However, on treatment with garcinol ~1.81 fold increase in miR-605 
signal intensity was observed as compared to ~1.46 fold (p-value: 1.90E-03) and ~2.42 
fold (p-value: 4.18E-04) downregulation on treatment with gemcitabine and combination 
respectively (Figure 37, Table 9). This result suggests the possibility of miR-605 being a 
tumor suppressor due to its upregulation on treatment with a natural agent as compared 
to downregulation by a chemotherapeutic drug. This miRNA is associated with Wnt 
signaling, MAPK signaling, EGFR pathway, Hedgehog signaling and cell cycle 
regulation (Table 17). So far in literature, miR-605 is thought to be a non-conserved 
miRNA, influencing the mRNA expression through its 5’UTR region which is specific to 
the 3’ end of miRNA [142]. However its exact role in cancer is not very clear.  
In the current study expression of miR-453 was observed to increase (p-value: 
2.27E-04) by several folds (~25-26 fold) on treatment with garcinol alone and in 
combination with gemcitabine but there was no change observed on treatment with 
gemcitabine alone (Figure 36, Table 8)... Target analysis revealed that miRNA-453 
targeted several pathways such as EGFR signaling, amino acid biosynthesis, regulation 
of actin cytoskeleton and Wnt signaling (Table 15). The role of miR-453 is not known in 
PaCa but a recent report has documented the role of miR-453 in breast carcinogenesis 
[143]. 
In order to validate the data obtained by microarray profiling, real time-reverse 
transcription PCR (q-RT-PCR) was done for these six miRNAs. Total RNAs from the 
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same preparation used for microarray analysis were reverse transcribed and the results 
obtained were comparable (R2 value 0.73 - 0.92, Table 11) with and followed the 
microarray analysis closely. Together, these results provide sufficient evidence 
supporting the superior antitumor activity of the combination treatment garcinol with 
gemcitabine in pancreatic cancer cells. The functional roles of all miRNAs are not 
completely understood, but may act as oncogenes and/or tumor suppressors regulating 
cellular differentiation, proliferation and apoptosis. Computational algorithms indicate 
that one miRNA may regulate hundreds of genes at different levels.  More importantly, 
from the point of personalized medicine and cancer therapy miRNAs may prove to be 
useful diagnostic and prognostic markers for cancer treatment.  
Overall, with the use of preclinical model system (the PaCa cell lines – BxPC-3 
and Panc-1) that recapitulates the complexity of this disease, we successfully 
established new priorities and strategies for development of new treatments. The 
genetic complexity of PaCa indicates that it is a heterogeneous cancer and that 
methods to individualize therapy will be required. These are findings reported in in vitro 
models and still need to be evaluated at preclinical and clinical levels.  
  
Figure 42: Pancreatic cancer signaling mechanism
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Appendix: Alterations in microRNAs measured by microarray analysis 
 
  
    Control   Garcinol Gemcitabine Combination 
No. Reporter Name Avg Signal Avg Signal Avg Signal Avg Signal 
1 hsa-let-7a 2,338 2,038 2,030 1,995 
2 hsa-let-7a* 8 5 8 12 
3 hsa-let-7a-2* 10 18 11 18 
4 hsa-let-7b 335 339 338 347 
5 hsa-let-7b* 20 16 18 14 
6 hsa-let-7c 467 495 485 422 
7 hsa-let-7c* 11 13 13 13 
8 hsa-let-7d 653 550 435 388 
9 hsa-let-7d* 13 19 17 16 
10 hsa-let-7e 415 320 345 269 
11 hsa-let-7e* 11 14 15 5 
12 hsa-let-7f 955 864 622 572 
13 hsa-let-7f-1* 21 18 29 12 
14 hsa-let-7f-2* 9 11 9 13 
15 hsa-let-7g 192 186 165 151 
16 hsa-let-7g* 7 20 5 14 
17 hsa-let-7i 164 180 155 170 
18 hsa-let-7i* 6 9 9 9 
19 hsa-miR-1 7 13 7 12 
20 hsa-miR-100 248 202 260 218 
21 hsa-miR-100* 9 13 5 13 
22 hsa-miR-101 9 14 6 12 
23 hsa-miR-101* 7 8 7 8 
24 hsa-miR-103 129 92 124 102 
25 hsa-miR-103-2* 13 9 12 13 
26 hsa-miR-103-as 10 9 12 18 
27 hsa-miR-105 14 13 14 12 
28 hsa-miR-105* 6 9 9 16 
29 hsa-miR-106a 68 55 74 66 
30 hsa-miR-106a* 3 12 7 18 
31 hsa-miR-106b 89 59 108 80 
32 hsa-miR-106b* 7 22 10 19 
33 hsa-miR-107 94 92 104 90 
34 hsa-miR-10a 389 335 320 262 
35 hsa-miR-10a* 5 17 14 14 
36 hsa-miR-10b 117 112 99 98 
37 hsa-miR-10b* 7 10 16 11 
38 hsa-miR-1178 4 10 11 12 
39 hsa-miR-1179 7 7 6 10 
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40 hsa-miR-1180 27 27 21 26 
41 hsa-miR-1181 30 34 37 20 
42 hsa-miR-1182 8 7 8 6 
43 hsa-miR-1183 12 10 8 11 
44 hsa-miR-1184 4 23 2 18 
45 hsa-miR-1185 10 10 10 10 
46 hsa-miR-1197 9 11 5 5 
47 hsa-miR-1200 5 11 6 24 
48 hsa-miR-1201 21 24 21 27 
49 hsa-miR-1202 4 10 4 22 
50 hsa-miR-1203 6 2 6 14 
51 hsa-miR-1204 9 13 5 11 
52 hsa-miR-1205 9 11 8 11 
53 hsa-miR-1206 7 9 7 14 
54 hsa-miR-1207-3p 7 19 3 14 
55 hsa-miR-1207-5p 14 16 14 22 
56 hsa-miR-1208 11 13 11 24 
57 hsa-miR-122 12 13 17 19 
58 hsa-miR-122* 5 12 9 11 
59 hsa-miR-1224-3p 18 26 31 3 
60 hsa-miR-1224-5p 30 15 34 25 
61 hsa-miR-1225-3p 13 14 19 12 
62 hsa-miR-1225-5p 6 12 9 14 
63 hsa-miR-1226 10 20 23 21 
64 hsa-miR-1226* 7 11 9 13 
65 hsa-miR-1227 15 20 26 13 
66 hsa-miR-1228 20 34 18 14 
67 hsa-miR-1228* 14 19 9 20 
68 hsa-miR-1229 31 38 56 14 
69 hsa-miR-1231 18 17 12 22 
70 hsa-miR-1233 19 20 18 12 
71 hsa-miR-1234 36 33 36 16 
72 hsa-miR-1236 17 17 13 7 
73 hsa-miR-1237 36 26 35 15 
74 hsa-miR-1238 32 19 24 15 
75 hsa-miR-124 16 55 10 38 
76 hsa-miR-124* 10 6 13 12 
77 hsa-miR-1243 7 13 9 3 
78 hsa-miR-1244 17 8 18 17 
79 hsa-miR-1245 10 7 12 5 
80 hsa-miR-1246 32 15 19 27 
81 hsa-miR-1247 21 36 33 12 
82 hsa-miR-1248 4 11 8 13 
83 hsa-miR-1249 40 34 53 17 
84 hsa-miR-1250 10 12 11 10 
85 hsa-miR-1251 7 6 4 7 
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86 hsa-miR-1252 10 7 8 12 
87 hsa-miR-1253 13 5 9 5 
88 hsa-miR-1254 9 7 11 14 
89 hsa-miR-1255a 11 8 11 9 
90 hsa-miR-1255b 4 14 6 4 
91 hsa-miR-1256 12 11 15 9 
92 hsa-miR-1257 14 12 16 13 
93 hsa-miR-1258 10 8 16 7 
94 hsa-miR-1259 10 8 27 14 
95 hsa-miR-125a-3p 13 10 14 16 
96 hsa-miR-125a-5p 263 206 220 189 
97 hsa-miR-125b 776 772 877 858 
98 hsa-miR-125b-1* 11 10 13 11 
99 hsa-miR-125b-2* 9 9 15 8 
100 hsa-miR-126 34 35 45 31 
101 hsa-miR-126* 7 8 7 7 
102 hsa-miR-1260 74 66 60 69 
103 hsa-miR-1261 7 3 9 10 
104 hsa-miR-1262 7 5 11 8 
105 hsa-miR-1263 7 17 10 9 
106 hsa-miR-1264 4 12 10 10 
107 hsa-miR-1265 7 4 7 17 
108 hsa-miR-1266 6 8 4 15 
109 hsa-miR-1267 10 19 7 8 
110 hsa-miR-1268 56 88 90 139 
111 hsa-miR-1269 7 11 3 9 
112 hsa-miR-1270 8 4 8 8 
113 hsa-miR-1271 9 10 4 9 
114 hsa-miR-1272 10 8 11 6 
115 hsa-miR-1273 9 10 10 7 
116 hsa-miR-127-3p 112 104 79 131 
117 hsa-miR-1274a 64 68 59 65 
118 hsa-miR-1274b 39 51 37 60 
119 hsa-miR-1275 149 182 172 210 
120 hsa-miR-127-5p 11 8 10 15 
121 hsa-miR-1276 11 17 10 14 
122 hsa-miR-1277 21 33 20 25 
123 hsa-miR-1278 10 5 11 11 
124 hsa-miR-1279 8 10 9 15 
125 hsa-miR-128 115 405 128 170 
126 hsa-miR-1280 5,772 7,922 5,321 6,597 
127 hsa-miR-1281 39 59 61 46 
128 hsa-miR-1282 11 7 14 6 
129 hsa-miR-1283 6 7 8 15 
130 hsa-miR-1284 1 11 8 21 
131 hsa-miR-1285 9 7 9 13 
131 
 
 
132 hsa-miR-1286 3 9 4 18 
133 hsa-miR-1287 9 13 9 14 
134 hsa-miR-1288 7 13 13 16 
135 hsa-miR-1289 12 17 60 75 
136 hsa-miR-129* 14 16 28 10 
137 hsa-miR-1290 6 10 12 19 
138 hsa-miR-1291 5 12 4 17 
139 hsa-miR-1292 9 6 9 18 
140 hsa-miR-1293 9 11 10 16 
141 hsa-miR-129-3p 16 29 23 8 
142 hsa-miR-1294 12 8 200 338 
143 hsa-miR-1295 4 13 8 23 
144 hsa-miR-129-5p 14 18 9 21 
145 hsa-miR-1296 6 13 4 13 
146 hsa-miR-1297 6 17 7 14 
147 hsa-miR-1298 8 12 6 14 
148 hsa-miR-1299 12 10 8 13 
149 hsa-miR-1301 8 8 6 16 
150 hsa-miR-1302 6 4 9 7 
151 hsa-miR-1303 12 9 18 14 
152 hsa-miR-1304 10 8 8 14 
153 hsa-miR-1305 17 25 12 26 
154 hsa-miR-1306 8 12 8 11 
155 hsa-miR-1307 20 26 31 35 
156 hsa-miR-1308 304 394 273 328 
157 hsa-miR-130a 12 12 17 21 
158 hsa-miR-130a* 8 12 12 13 
159 hsa-miR-130b 13 8 13 18 
160 hsa-miR-130b* 7 9 11 13 
161 hsa-miR-132 24 64 49 59 
162 hsa-miR-132* 6 6 6 18 
163 hsa-miR-1321 3 10 5 23 
164 hsa-miR-1322 8 7 10 8 
165 hsa-miR-1323 12 8 15 13 
166 hsa-miR-1324 7 7 4 13 
167 hsa-miR-133a 16 19 21 14 
168 hsa-miR-133b 17 14 22 11 
169 hsa-miR-134 68 45 74 61 
170 hsa-miR-135a 12 6 9 8 
171 hsa-miR-135a* 11 15 7 13 
172 hsa-miR-135b 10 5 9 4 
173 hsa-miR-135b* 13 5 8 11 
174 hsa-miR-136 9 9 11 12 
175 hsa-miR-136* 12 12 6 14 
176 hsa-miR-137 13 14 11 13 
177 hsa-miR-138 15 16 14 15 
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178 hsa-miR-138-1* 9 18 6 14 
179 hsa-miR-138-2* 6 10 9 12 
180 hsa-miR-139-3p 8 9 3 15 
181 hsa-miR-139-5p 11 11 7 13 
182 hsa-miR-140-3p 7 21 2 29 
183 hsa-miR-140-5p 6 13 5 8 
184 hsa-miR-141 10 6 6 7 
185 hsa-miR-141* 8 9 5 10 
186 hsa-miR-142-3p 9 4 12 8 
187 hsa-miR-142-5p 9 6 8 12 
188 hsa-miR-143 14 13 10 13 
189 hsa-miR-143* 9 7 9 5 
190 hsa-miR-144 7 9 9 9 
191 hsa-miR-144* 7 8 10 5 
192 hsa-miR-145 11 16 13 10 
193 hsa-miR-145* 10 10 13 8 
194 hsa-miR-1468 7 10 8 9 
195 hsa-miR-1469 52 61 66 123 
196 hsa-miR-146a 415 402 410 394 
197 hsa-miR-146a* 8 14 11 11 
198 hsa-miR-146b-3p 6 10 10 11 
199 hsa-miR-146b-5p 12 11 16 14 
200 hsa-miR-147 12 8 28 13 
201 hsa-miR-1470 26 31 29 12 
202 hsa-miR-1471 7 13 8 16 
203 hsa-miR-147b 10 12 11 15 
204 hsa-miR-148a 9 10 11 7 
205 hsa-miR-148a* 10 9 16 10 
206 hsa-miR-148b 26 21 21 22 
207 hsa-miR-148b* 12 6 18 5 
208 hsa-miR-149 13 16 27 14 
209 hsa-miR-149* 103 160 68 143 
210 hsa-miR-150 14 12 31 11 
211 hsa-miR-150* 11 14 14 19 
212 hsa-miR-151-3p 95 111 76 98 
213 hsa-miR-151-5p 502 511 563 596 
214 hsa-miR-152 18 15 12 20 
215 hsa-miR-153 10 4 8 14 
216 hsa-miR-1537 10 10 9 9 
217 hsa-miR-1538 7 11 6 12 
218 hsa-miR-1539 7 13 3 10 
219 hsa-miR-154 18 11 14 13 
220 hsa-miR-154* 16 13 17 11 
221 hsa-miR-155 39 44 46 54 
222 hsa-miR-155* 7 17 7 12 
223 hsa-miR-15a 14 12 13 12 
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224 hsa-miR-15a* 6 13 5 12 
225 hsa-miR-15b 1,107 932 1,168 930 
226 hsa-miR-15b* 10 6 12 10 
227 hsa-miR-16 678 567 761 689 
228 hsa-miR-16-1* 7 10 8 8 
229 hsa-miR-16-2* 14 14 14 17 
230 hsa-miR-17 66 65 53 69 
231 hsa-miR-17* 3 14 8 5 
232 hsa-miR-181a 56 41 58 61 
233 hsa-miR-181a* 7 13 12 13 
234 hsa-miR-181a-2* 8 10 7 15 
235 hsa-miR-181b 20 19 25 22 
236 hsa-miR-181c 16 14 19 22 
237 hsa-miR-181c* 7 9 6 13 
238 hsa-miR-181d 12 11 11 14 
239 hsa-miR-182 324 290 327 272 
240 hsa-miR-182* 10 9 6 11 
241 hsa-miR-1825 27 30 25 19 
242 hsa-miR-1826 19,512 17,879 16,472 17,219 
243 hsa-miR-1827 5 16 9 17 
244 hsa-miR-183 123 109 103 98 
245 hsa-miR-183* 9 7 8 11 
246 hsa-miR-184 10 9 7 6 
247 hsa-miR-185 41 35 28 33 
248 hsa-miR-185* 9 8 6 12 
249 hsa-miR-186 7 10 8 14 
250 hsa-miR-186* 5 14 6 16 
251 hsa-miR-187 9 9 7 14 
252 hsa-miR-187* 11 15 10 11 
253 hsa-miR-188-3p 2 18 5 22 
254 hsa-miR-188-5p 15 17 17 26 
255 hsa-miR-18a 14 15 18 18 
256 hsa-miR-18a* 8 12 8 10 
257 hsa-miR-18b 7 9 16 11 
258 hsa-miR-18b* 12 21 28 13 
259 hsa-miR-190 6 2 11 10 
260 hsa-miR-1908 15 19 12 27 
261 hsa-miR-1909 4 10 5 8 
262 hsa-miR-1909* 10 7 12 10 
263 hsa-miR-190b 8 6 11 15 
264 hsa-miR-191 1,180 926 1,140 973 
265 hsa-miR-191* 16 14 30 13 
266 hsa-miR-1910 8 14 2 22 
267 hsa-miR-1911 13 14 15 14 
268 hsa-miR-1911* 6 8 10 9 
269 hsa-miR-1912 9 16 9 6 
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270 hsa-miR-1913 29 27 47 16 
271 hsa-miR-1914 37 23 37 12 
272 hsa-miR-1914* 16 12 11 9 
273 hsa-miR-1915 166 239 197 305 
274 hsa-miR-1915* 7 13 10 13 
275 hsa-miR-192 17 17 12 17 
276 hsa-miR-192* 8 8 8 7 
277 hsa-miR-193a-3p 13 13 13 7 
278 hsa-miR-193a-5p 106 91 89 112 
279 hsa-miR-193b 14 18 13 7 
280 hsa-miR-193b* 23 17 17 19 
281 hsa-miR-194 15 16 14 13 
282 hsa-miR-194* 11 10 10 10 
283 hsa-miR-195 36 23 25 33 
284 hsa-miR-195* 23 15 11 9 
285 hsa-miR-196a 500 373 336 284 
286 hsa-miR-196a* 16 5 6 9 
287 hsa-miR-196b 18 12 16 10 
288 hsa-miR-196b* 10 10 7 12 
289 hsa-miR-197 42 37 64 24 
290 hsa-miR-1972 5 14 4 23 
291 hsa-miR-1973 8 10 5 16 
292 hsa-miR-1974 3,919 3,113 4,272 3,421 
293 hsa-miR-1975 2,997 2,808 3,489 2,903 
294 hsa-miR-1976 15 27 22 15 
295 hsa-miR-1977 906 519 848 612 
296 hsa-miR-1978 187 122 169 232 
297 hsa-miR-1979 6,640 5,762 6,615 6,208 
298 hsa-miR-198 8 10 11 10 
299 hsa-miR-199a-3p 8 10 13 9 
300 hsa-miR-199a-5p 9 11 13 10 
301 hsa-miR-199b-5p 7 14 12 12 
302 hsa-miR-19a 11 13 12 12 
303 hsa-miR-19a* 11 6 29 13 
304 hsa-miR-19b 124 113 102 99 
305 hsa-miR-19b-1* 8 20 10 11 
306 hsa-miR-19b-2* 11 5 14 11 
307 hsa-miR-200a 9 11 10 7 
308 hsa-miR-200a* 9 11 10 14 
309 hsa-miR-200b 8 14 15 14 
310 hsa-miR-200b* 7 11 4 14 
311 hsa-miR-200c 11 11 7 7 
312 hsa-miR-200c* 13 17 10 12 
313 hsa-miR-202 11 12 8 6 
314 hsa-miR-202* 6 9 9 6 
315 hsa-miR-203 7 12 10 16 
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316 hsa-miR-204 12 14 10 18 
317 hsa-miR-205 13 15 7 12 
318 hsa-miR-205* 11 8 12 12 
319 hsa-miR-2052 9 11 8 12 
320 hsa-miR-2053 9 7 12 10 
321 hsa-miR-2054 9 11 6 14 
322 hsa-miR-206 10 13 7 13 
323 hsa-miR-208a 9 2 11 10 
324 hsa-miR-208b 15 10 9 8 
325 hsa-miR-20a 89 67 84 90 
326 hsa-miR-20a* 12 10 8 14 
327 hsa-miR-20b 17 19 20 22 
328 hsa-miR-20b* 12 9 10 8 
329 hsa-miR-21 3,857 2,609 3,792 3,007 
330 hsa-miR-21* 4 17 5 12 
331 hsa-miR-210 15 14 15 25 
332 hsa-miR-211 10 16 9 10 
333 hsa-miR-2110 8 20 14 20 
334 hsa-miR-2113 7 7 9 13 
335 hsa-miR-2114 12 18 16 8 
336 hsa-miR-2114* 3 12 8 19 
337 hsa-miR-2115 9 13 5 6 
338 hsa-miR-2115* 7 10 5 20 
339 hsa-miR-2116 7 7 14 23 
340 hsa-miR-2116* 11 15 16 13 
341 hsa-miR-2117 9 10 7 13 
342 hsa-miR-212 15 18 12 11 
343 hsa-miR-214 7 18 14 15 
344 hsa-miR-214* 5 22 3 27 
345 hsa-miR-215 10 10 11 8 
346 hsa-miR-216a 6 11 5 10 
347 hsa-miR-216b 8 7 9 9 
348 hsa-miR-217 9 10 6 15 
349 hsa-miR-218 8 11 7 15 
350 hsa-miR-218-1* 11 15 6 14 
351 hsa-miR-218-2* 10 19 6 20 
352 hsa-miR-219-1-3p 7 9 9 10 
353 hsa-miR-219-2-3p 12 11 11 13 
354 hsa-miR-219-5p 6 13 8 16 
355 hsa-miR-22 27 26 24 28 
356 hsa-miR-22* 15 15 13 11 
357 hsa-miR-220a 5 19 14 14 
358 hsa-miR-220b 7 15 13 20 
359 hsa-miR-220c 5 10 13 13 
360 hsa-miR-221 121 97 132 139 
361 hsa-miR-221* 10 8 20 13 
362 hsa-miR-222 
363 hsa-miR-222* 
364 hsa-miR-223 
365 hsa-miR-223* 
366 hsa-miR-224 
367 hsa-miR-224* 
368 hsa-miR-2276 
369 hsa-miR-2277 
370 hsa-miR-2278 
371 hsa-miR-23a 
372 hsa-miR-23a* 
373 hsa-miR-23b 
374 hsa-miR-23b* 
375 hsa-miR-24 
376 hsa-miR-24-1* 
377 hsa-miR-24-2* 
378 hsa-miR-25 
379 hsa-miR-25* 
380 hsa-miR-26a 
381 hsa-miR-26a-1* 
382 hsa-miR-26a-2* 
383 hsa-miR-26b 
384 hsa-miR-26b* 
385 hsa-miR-27a 
386 hsa-miR-27a* 
387 hsa-miR-27b 
388 hsa-miR-27b* 
389 hsa-miR-28-3p 
390 hsa-miR-28-5p 
391 hsa-miR-296-3p 
392 hsa-miR-296-5p 
393 hsa-miR-297 
394 hsa-miR-298 
395 hsa-miR-299-3p 
396 hsa-miR-299-5p 
397 hsa-miR-29a 
398 hsa-miR-29a* 
399 hsa-miR-29b 
400 hsa-miR-29b-1* 
401 hsa-miR-29b-2* 
402 hsa-miR-29c 
403 hsa-miR-29c* 
404 hsa-miR-300 
405 hsa-miR-301a 
406 hsa-miR-301b 
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155 117 198 
5 8 11 
22 30 35 
7 8 8 
9 13 6 
11 12 11 
12 15 11 
12 13 9 
13 9 11 
3,183 4,233 3,376 
36 39 29 
1,266 1,490 1,171 
10 6 11 
931 752 1,111 
9 9 8 
15 19 8 
298 217 268 
12 12 9 
507 644 537 
7 14 2 
5 15 8 
33 22 20 
7 14 1 
176 114 148 
5 12 6 
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67 90 
9 17 11 
8 10 9 
12 20 13 
6 8 7 
30 25 49 
8 12 14 
3 16 8 
8 13 18 
36 41 59 
646 732 738 
4 12 20 
8 17 27 
34 61 48 
5 4 8 
12 14 9 
8 8 9 
6 8 19 
7 8 11 
6 8 9 
148 
10 
11 
10 
10 
4 
15 
16 
11 
4,476 
42 
1,472 
16 
860 
11 
17 
218 
20 
585 
12 
8 
21 
16 
109 
21 
80 
20 
15 
19 
14 
17 
12 
14 
15 
28 
775 
11 
23 
64 
9 
9 
9 
7 
8 
9 
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407 hsa-miR-302a 7 3 10 10 
408 hsa-miR-302a* 7 8 12 11 
409 hsa-miR-302b 11 14 14 8 
410 hsa-miR-302b* 8 7 12 9 
411 hsa-miR-302c 11 8 12 12 
412 hsa-miR-302c* 12 14 9 9 
413 hsa-miR-302d 19 12 6 8 
414 hsa-miR-302d* 10 14 8 12 
415 hsa-miR-302e 12 12 9 13 
416 hsa-miR-302f 14 14 10 24 
417 hsa-miR-30a 56 52 47 55 
418 hsa-miR-30a* 29 41 24 42 
419 hsa-miR-30b 89 83 79 77 
420 hsa-miR-30b* 6 7 8 14 
421 hsa-miR-30c 393 375 388 351 
422 hsa-miR-30c-1* 11 17 13 19 
423 hsa-miR-30c-2* 12 13 44 87 
424 hsa-miR-30d 52 59 45 36 
425 hsa-miR-30d* 9 8 7 7 
426 hsa-miR-30e 30 23 23 23 
427 hsa-miR-30e* 14 16 13 24 
428 hsa-miR-31 379 350 464 448 
429 hsa-miR-31* 11 14 17 19 
430 hsa-miR-32 7 9 12 10 
431 hsa-miR-32* 2 18 9 13 
432 hsa-miR-320a 189 163 173 175 
433 hsa-miR-320b 103 99 97 118 
434 hsa-miR-320c 128 132 113 112 
435 hsa-miR-320d 25 25 11 18 
436 hsa-miR-323-3p 9 14 23 15 
437 hsa-miR-323-5p 7 16 7 24 
438 hsa-miR-324-3p 11 21 13 21 
439 hsa-miR-324-5p 22 21 16 18 
440 hsa-miR-325 7 8 5 12 
441 hsa-miR-326 13 21 7 13 
442 hsa-miR-328 15 26 15 13 
443 hsa-miR-329 31 28 26 32 
444 hsa-miR-330-3p 6 11 4 11 
445 hsa-miR-330-5p 10 22 4 17 
446 hsa-miR-331-3p 14 20 11 20 
447 hsa-miR-331-5p 9 9 9 13 
448 hsa-miR-335 5 13 11 12 
449 hsa-miR-335* 6 13 12 14 
450 hsa-miR-337-3p 7 15 12 13 
451 hsa-miR-337-5p 10 10 12 13 
452 hsa-miR-338-3p 6 10 7 10 
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453 hsa-miR-338-5p 9 9 9 14 
454 hsa-miR-339-3p 6 24 5 24 
455 hsa-miR-339-5p 13 20 12 14 
456 hsa-miR-33a 8 7 11 10 
457 hsa-miR-33a* 3 5 9 14 
458 hsa-miR-33b 9 7 12 13 
459 hsa-miR-33b* 10 22 11 15 
460 hsa-miR-340 5 9 12 7 
461 hsa-miR-340* 8 12 12 16 
462 hsa-miR-342-3p 47 65 54 51 
463 hsa-miR-342-5p 12 13 19 11 
464 hsa-miR-345 20 43 15 18 
465 hsa-miR-346 9 18 15 9 
466 hsa-miR-34a 12 7 9 10 
467 hsa-miR-34a* 8 16 6 4 
468 hsa-miR-34b 13 14 8 13 
469 hsa-miR-34b* 11 13 10 4 
470 hsa-miR-34c-3p 15 21 16 16 
471 hsa-miR-34c-5p 10 7 11 14 
472 hsa-miR-361-3p 14 22 19 10 
473 hsa-miR-361-5p 278 248 280 257 
474 hsa-miR-362-3p 11 11 14 9 
475 hsa-miR-362-5p 23 16 13 15 
476 hsa-miR-363 20 7 11 15 
477 hsa-miR-363* 11 10 4 10 
478 hsa-miR-365 18 20 24 8 
479 hsa-miR-365* 16 10 9 15 
480 hsa-miR-367 13 11 8 9 
481 hsa-miR-367* 10 9 10 10 
482 hsa-miR-369-3p 14 9 9 10 
483 hsa-miR-369-5p 10 6 6 9 
484 hsa-miR-370 9 14 8 14 
485 hsa-miR-371-3p 6 18 9 17 
486 hsa-miR-371-5p 11 16 9 19 
487 hsa-miR-372 10 8 14 14 
488 hsa-miR-373 7 10 13 9 
489 hsa-miR-373* 6 13 9 19 
490 hsa-miR-374a 4 10 9 9 
491 hsa-miR-374a* 4 11 6 11 
492 hsa-miR-374b 5 12 13 13 
493 hsa-miR-374b* 6 3 7 22 
494 hsa-miR-375 8 15 11 17 
495 hsa-miR-376a 51 33 27 33 
496 hsa-miR-376a* 9 10 17 14 
497 hsa-miR-376b 7 7 12 15 
498 hsa-miR-376c 82 68 70 67 
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499 hsa-miR-377 20 1,986 25 768 
500 hsa-miR-377* 11 9 12 11 
501 hsa-miR-378 28 23 36 29 
502 hsa-miR-378* 17 15 10 13 
503 hsa-miR-379 68 55 81 52 
504 hsa-miR-379* 24 23 20 21 
505 hsa-miR-380 9 10 16 13 
506 hsa-miR-380* 7 14 10 14 
507 hsa-miR-381 9 12 16 11 
508 hsa-miR-382 86 70 90 96 
509 hsa-miR-383 12 6 9 16 
510 hsa-miR-384 8 13 6 12 
511 hsa-miR-409-3p 41 40 27 23 
512 hsa-miR-409-5p 16 12 9 15 
513 hsa-miR-410 14 16 11 17 
514 hsa-miR-411 16 14 11 19 
515 hsa-miR-411* 48 27 32 32 
516 hsa-miR-412 10 11 11 9 
517 hsa-miR-421 16 19 16 16 
518 hsa-miR-422a 13 15 6 15 
519 hsa-miR-423-3p 22 18 16 10 
520 hsa-miR-423-5p 504 355 696 544 
521 hsa-miR-424 10 11 8 16 
522 hsa-miR-424* 22 28 22 44 
523 hsa-miR-425 121 115 132 115 
524 hsa-miR-425* 33 21 30 14 
525 hsa-miR-429 12 8 10 7 
526 hsa-miR-431 26 26 33 35 
527 hsa-miR-431* 10 14 15 25 
528 hsa-miR-432 323 282 424 377 
529 hsa-miR-432* 8 11 7 7 
530 hsa-miR-433 34 27 35 36 
531 hsa-miR-448 6 9 11 16 
532 hsa-miR-449a 10 7 12 9 
533 hsa-miR-449b 18 9 13 10 
534 hsa-miR-449b* 23 28 12 13 
535 hsa-miR-449c 10 10 11 13 
536 hsa-miR-449c* 9 17 22 14 
537 hsa-miR-450a 6 6 9 6 
538 hsa-miR-450b-3p 8 12 15 9 
539 hsa-miR-450b-5p 7 11 9 12 
540 hsa-miR-451 10 11 6 14 
541 hsa-miR-452 9 10 8 10 
542 hsa-miR-452* 7 9 8 12 
543 hsa-miR-453 8 199 4 210 
544 hsa-miR-454 38 22 21 23 
140 
 
 
545 hsa-miR-454* 11 12 7 7 
546 hsa-miR-455-3p 8 13 5 18 
547 hsa-miR-455-5p 10 13 9 8 
548 hsa-miR-483-3p 30 31 21 13 
549 hsa-miR-483-5p 135 140 89 139 
550 hsa-miR-484 30 25 30 17 
551 hsa-miR-485-3p 35 45 32 17 
552 hsa-miR-485-5p 25 19 15 19 
553 hsa-miR-486-3p 17 21 9 11 
554 hsa-miR-486-5p 39 30 31 29 
555 hsa-miR-487a 12 15 15 13 
556 hsa-miR-487b 88 59 88 85 
557 hsa-miR-488 8 7 11 4 
558 hsa-miR-488* 10 14 11 14 
559 hsa-miR-489 11 7 14 13 
560 hsa-miR-490-3p 6 11 12 10 
561 hsa-miR-490-5p 10 12 10 12 
562 hsa-miR-491-3p 6 14 13 6 
563 hsa-miR-491-5p 15 13 17 11 
564 hsa-miR-492 12 8 10 8 
565 hsa-miR-493 13 19 17 16 
566 hsa-miR-493* 31 19 28 19 
567 hsa-miR-494 94 48 72 64 
568 hsa-miR-495 218 99 186 90 
569 hsa-miR-496 16 12 13 12 
570 hsa-miR-497 9 11 6 15 
571 hsa-miR-497* 10 13 7 11 
572 hsa-miR-498 32 56 41 52 
573 hsa-miR-499-3p 13 12 7 10 
574 hsa-miR-499-5p 14 11 11 10 
575 hsa-miR-500 15 14 7 17 
576 hsa-miR-500* 15 13 9 16 
577 hsa-miR-501-3p 14 16 7 16 
578 hsa-miR-501-5p 24 15 14 16 
579 hsa-miR-502-3p 14 19 6 13 
580 hsa-miR-502-5p 14 12 9 12 
581 hsa-miR-503 38 20 20 22 
582 hsa-miR-504 7 10 8 10 
583 hsa-miR-505 18 11 6 12 
584 hsa-miR-505* 28 19 14 22 
585 hsa-miR-506 10 17 14 10 
586 hsa-miR-507 7 8 7 11 
587 hsa-miR-508-3p 7 10 7 15 
588 hsa-miR-508-5p 3 10 2 17 
589 hsa-miR-509-3-5p 5 11 6 14 
590 hsa-miR-509-3p 10 6 8 12 
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591 hsa-miR-509-5p 6 10 2 15 
592 hsa-miR-510 7 14 7 23 
593 hsa-miR-511 8 8 9 10 
594 hsa-miR-512-3p 5 7 9 9 
595 hsa-miR-512-5p 6 11 7 18 
596 hsa-miR-513a-3p 7 7 12 15 
597 hsa-miR-513a-5p 6 10 5 14 
598 hsa-miR-513b 8 14 9 9 
599 hsa-miR-513c 7 12 14 16 
600 hsa-miR-514 9 11 15 14 
601 hsa-miR-515-3p 10 9 22 13 
602 hsa-miR-515-5p 11 7 14 9 
603 hsa-miR-516a-3p 10 3 15 5 
604 hsa-miR-516a-5p 9 7 16 11 
605 hsa-miR-516b 12 7 14 14 
606 hsa-miR-517* 10 6 6 5 
607 hsa-miR-517a 13 10 15 12 
608 hsa-miR-517b 14 16 14 15 
609 hsa-miR-517c 12 5 16 13 
610 hsa-miR-518a-3p 8 19 7 12 
611 hsa-miR-518a-5p 10 8 11 6 
612 hsa-miR-518b 21 17 12 16 
613 hsa-miR-518c 13 9 6 8 
614 hsa-miR-518c* 21 12 10 16 
615 hsa-miR-518d-3p 11 5 7 13 
616 hsa-miR-518d-5p 11 10 4 10 
617 hsa-miR-518e 11 14 4 9 
618 hsa-miR-518e* 13 8 67 169 
619 hsa-miR-518f 9 8 8 5 
620 hsa-miR-518f* 9 9 5 14 
621 hsa-miR-519a 9 9 10 5 
622 hsa-miR-519b-3p 11 9 7 11 
623 hsa-miR-519c-3p 17 9 7 12 
624 hsa-miR-519d 23 13 13 8 
625 hsa-miR-519e 20 12 9 13 
626 hsa-miR-519e* 13 6 6 8 
627 hsa-miR-520a-3p 15 12 13 11 
628 hsa-miR-520a-5p 24 13 6 6 
629 hsa-miR-520b 15 9 14 12 
630 hsa-miR-520c-3p 10 6 10 10 
631 hsa-miR-520d-3p 12 6 12 13 
632 hsa-miR-520d-5p 7 11 11 17 
633 hsa-miR-520e 11 7 12 6 
634 hsa-miR-520f 11 17 18 11 
635 hsa-miR-520g 12 8 14 8 
636 hsa-miR-520h 11 9 13 6 
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637 hsa-miR-521 20 9 13 9 
638 hsa-miR-522 21 13 15 11 
639 hsa-miR-523 9 15 3 17 
640 hsa-miR-524-3p 21 8 9 10 
641 hsa-miR-524-5p 10 7 6 5 
642 hsa-miR-525-3p 10 8 6 7 
643 hsa-miR-525-5p 8 10 6 12 
644 hsa-miR-526b 11 9 10 7 
645 hsa-miR-526b* 11 5 9 7 
646 hsa-miR-532-3p 13 22 9 17 
647 hsa-miR-532-5p 19 13 11 23 
648 hsa-miR-539 21 14 24 16 
649 hsa-miR-541 9 8 5 7 
650 hsa-miR-541* 11 10 6 12 
651 hsa-miR-542-3p 11 12 3 11 
652 hsa-miR-542-5p 11 8 9 12 
653 hsa-miR-543 16 13 10 20 
654 hsa-miR-544 9 12 16 5 
655 hsa-miR-545 10 8 12 14 
656 hsa-miR-545* 13 7 12 10 
657 hsa-miR-548a-3p 11 7 7 13 
658 hsa-miR-548a-5p 25 10 12 10 
659 hsa-miR-548b-3p 18 9 14 13 
660 hsa-miR-548b-5p 13 7 17 9 
661 hsa-miR-548c-3p 8 8 10 9 
662 hsa-miR-548c-5p 13 8 13 8 
663 hsa-miR-548d-3p 11 4 10 10 
664 hsa-miR-548d-5p 14 5 11 8 
665 hsa-miR-548e 13 7 23 10 
666 hsa-miR-548f 20 24 10 12 
667 hsa-miR-548g 11 5 3 14 
668 hsa-miR-548h 41 42 32 23 
669 hsa-miR-548i 11 8 12 6 
670 hsa-miR-548j 16 5 18 14 
671 hsa-miR-548k 18 11 11 9 
672 hsa-miR-548l 16 10 11 10 
673 hsa-miR-548m 52 97 64 74 
674 hsa-miR-548n 13 15 9 10 
675 hsa-miR-548o 8 5 4 11 
676 hsa-miR-548p 17 9 11 12 
677 hsa-miR-548q 15 17 11 22 
678 hsa-miR-549 13 8 12 12 
679 hsa-miR-550 18 23 12 17 
680 hsa-miR-550* 20 17 20 9 
681 hsa-miR-551a 23 17 41 11 
682 hsa-miR-551b 11 9 5 12 
143 
 
 
683 hsa-miR-551b* 12 11 5 15 
684 hsa-miR-552 6 2 6 5 
685 hsa-miR-553 7 8 8 12 
686 hsa-miR-554 7 7 7 13 
687 hsa-miR-555 16 15 19 11 
688 hsa-miR-556-3p 8 6 8 13 
689 hsa-miR-556-5p 8 7 10 9 
690 hsa-miR-557 9 16 12 18 
691 hsa-miR-558 6 15 7 15 
692 hsa-miR-559 7 13 11 9 
693 hsa-miR-561 7 8 4 17 
694 hsa-miR-562 6 6 7 15 
695 hsa-miR-563 11 18 17 7 
696 hsa-miR-564 9 9 25 15 
697 hsa-miR-566 17 18 10 12 
698 hsa-miR-567 9 6 14 7 
699 hsa-miR-568 13 8 16 13 
700 hsa-miR-569 7 12 15 11 
701 hsa-miR-570 6 12 9 8 
702 hsa-miR-571 7 9 20 13 
703 hsa-miR-572 4 11 9 10 
704 hsa-miR-573 4 6 8 14 
705 hsa-miR-574-3p 67 49 68 54 
706 hsa-miR-574-5p 120 137 98 120 
707 hsa-miR-575 41 58 37 67 
708 hsa-miR-576-3p 5 4 7 6 
709 hsa-miR-576-5p 8 8 17 10 
710 hsa-miR-577 6 9 7 13 
711 hsa-miR-578 4 8 6 7 
712 hsa-miR-579 8 10 8 9 
713 hsa-miR-580 8 10 9 10 
714 hsa-miR-581 4 5 9 4 
715 hsa-miR-582-3p 8 11 9 8 
716 hsa-miR-582-5p 9 8 11 10 
717 hsa-miR-583 5 8 7 12 
718 hsa-miR-584 10 13 10 14 
719 hsa-miR-585 7 15 9 12 
720 hsa-miR-586 5 10 8 8 
721 hsa-miR-587 6 10 9 8 
722 hsa-miR-588 4 15 6 9 
723 hsa-miR-589 8 15 11 16 
724 hsa-miR-589* 9 13 7 16 
725 hsa-miR-590-3p 5 7 7 4 
726 hsa-miR-590-5p 10 8 10 11 
727 hsa-miR-591 7 16 12 13 
728 hsa-miR-592 8 8 12 6 
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729 hsa-miR-593 14 14 12 13 
730 hsa-miR-593* 6 5 8 7 
731 hsa-miR-595 13 9 15 14 
732 hsa-miR-596 31 32 42 17 
733 hsa-miR-597 11 10 15 12 
734 hsa-miR-598 8 11 14 11 
735 hsa-miR-599 6 6 14 12 
736 hsa-miR-600 11 11 17 15 
737 hsa-miR-601 15 11 21 16 
738 hsa-miR-602 14 19 14 18 
739 hsa-miR-603 6 7 6 12 
740 hsa-miR-604 10 10 12 28 
741 hsa-miR-605 69 123 26 13 
742 hsa-miR-606 11 5 10 7 
743 hsa-miR-607 10 11 10 9 
744 hsa-miR-608 17 7 19 14 
745 hsa-miR-609 17 8 14 11 
746 hsa-miR-610 9 10 8 14 
747 hsa-miR-611 17 17 19 15 
748 hsa-miR-612 11 16 10 14 
749 hsa-miR-613 20 8 13 11 
750 hsa-miR-614 12 10 10 5 
751 hsa-miR-615-3p 29 25 23 23 
752 hsa-miR-615-5p 10 21 14 11 
753 hsa-miR-616 10 6 9 14 
754 hsa-miR-616* 12 10 12 13 
755 hsa-miR-617 20 14 13 16 
756 hsa-miR-618 12 7 10 6 
757 hsa-miR-619 12 9 18 9 
758 hsa-miR-620 9 6 11 7 
759 hsa-miR-621 9 5 11 12 
760 hsa-miR-622 10 4 16 10 
761 hsa-miR-623 15 11 14 16 
762 hsa-miR-624 8 5 8 15 
763 hsa-miR-624* 10 7 14 9 
764 hsa-miR-625 10 2 13 15 
765 hsa-miR-625* 29 15 40 22 
766 hsa-miR-626 7 6 10 9 
767 hsa-miR-627 23 15 17 7 
768 hsa-miR-628-3p 12 9 11 11 
769 hsa-miR-628-5p 13 5 20 13 
770 hsa-miR-629 14 13 15 12 
771 hsa-miR-629* 36 38 30 11 
772 hsa-miR-630 16 12 16 8 
773 hsa-miR-631 13 17 14 10 
774 hsa-miR-632 10 8 9 5 
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775 hsa-miR-633 9 9 10 6 
776 hsa-miR-634 26 26 25 12 
777 hsa-miR-635 13 7 12 10 
778 hsa-miR-636 20 25 29 12 
779 hsa-miR-637 16 14 15 14 
780 hsa-miR-638 758 994 812 1,189 
781 hsa-miR-639 11 13 11 8 
782 hsa-miR-640 132 324 14 7 
783 hsa-miR-641 19 14 21 11 
784 hsa-miR-642 30 17 29 14 
785 hsa-miR-643 5 7 10 7 
786 hsa-miR-644 7 6 9 14 
787 hsa-miR-645 5 9 6 9 
788 hsa-miR-646 3 6 7 5 
789 hsa-miR-647 11 17 14 9 
790 hsa-miR-648 5 15 14 9 
791 hsa-miR-649 6 2 8 8 
792 hsa-miR-650 8 14 13 10 
793 hsa-miR-651 6 7 11 5 
794 hsa-miR-652 8 11 11 17 
795 hsa-miR-653 16 9 9 8 
796 hsa-miR-654-3p 36 39 45 37 
797 hsa-miR-654-5p 22 19 25 18 
798 hsa-miR-655 7 9 20 7 
799 hsa-miR-656 7 11 27 10 
800 hsa-miR-657 18 21 45 11 
801 hsa-miR-658 9 15 6 12 
802 hsa-miR-659 11 17 9 15 
803 hsa-miR-660 10 18 21 13 
804 hsa-miR-661 4 12 13 9 
805 hsa-miR-662 8 24 17 11 
806 hsa-miR-663 72 115 79 131 
807 hsa-miR-663b 5 19 7 14 
808 hsa-miR-664 11 16 21 6 
809 hsa-miR-664* 6 13 15 12 
810 hsa-miR-665 15 24 13 12 
811 hsa-miR-668 26 21 17 11 
812 hsa-miR-670 8 12 5 7 
813 hsa-miR-671-3p 13 25 11 15 
814 hsa-miR-671-5p 27 32 16 33 
815 hsa-miR-675 21 18 9 12 
816 hsa-miR-675* 26 29 29 8 
817 hsa-miR-7 15 14 13 15 
818 hsa-miR-708 9 7 8 9 
819 hsa-miR-708* 4 8 8 9 
820 hsa-miR-7-1* 7 13 8 24 
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821 hsa-miR-711 6 21 3 14 
822 hsa-miR-718 30 38 34 16 
823 hsa-miR-7-2* 6 16 6 12 
824 hsa-miR-720 1,824 2,463 1,989 2,427 
825 hsa-miR-744 9 15 7 12 
826 hsa-miR-744* 11 9 12 14 
827 hsa-miR-758 14 16 16 17 
828 hsa-miR-759 6 10 8 1 
829 hsa-miR-760 7 8 6 17 
830 hsa-miR-761 6 7 11 11 
831 hsa-miR-762 70 120 89 131 
832 hsa-miR-764 26 36 14 13 
833 hsa-miR-765 40 39 39 57 
834 hsa-miR-766 36 31 64 14 
835 hsa-miR-767-3p 19 27 17 12 
836 hsa-miR-767-5p 8 6 11 6 
837 hsa-miR-769-3p 9 14 14 20 
838 hsa-miR-769-5p 12 13 13 12 
839 hsa-miR-770-5p 11 13 6 12 
840 hsa-miR-802 8 3 3 6 
841 hsa-miR-873 10 12 9 9 
842 hsa-miR-874 6 12 5 23 
843 hsa-miR-875-3p 8 9 5 10 
844 hsa-miR-875-5p 14 18 12 9 
845 hsa-miR-876-3p 7 8 8 8 
846 hsa-miR-876-5p 9 9 10 13 
847 hsa-miR-877 65 47 78 71 
848 hsa-miR-877* 21 23 24 10 
849 hsa-miR-885-3p 10 13 6 20 
850 hsa-miR-885-5p 18 15 8 9 
851 hsa-miR-886-3p 8 8 5 8 
852 hsa-miR-886-5p 7 3 8 14 
853 hsa-miR-887 9 22 4 19 
854 hsa-miR-888 8 15 7 10 
855 hsa-miR-888* 7 8 8 16 
856 hsa-miR-889 7 6 8 5 
857 hsa-miR-890 9 5 5 13 
858 hsa-miR-891a 6 8 11 4 
859 hsa-miR-891b 5 8 8 6 
860 hsa-miR-892a 9 8 3 10 
861 hsa-miR-892b 6 9 4 6 
862 hsa-miR-9 9 8 9 11 
863 hsa-miR-9* 16 15 9 9 
864 hsa-miR-920 8 8 6 9 
865 hsa-miR-921 9 5 7 11 
866 hsa-miR-922 9 10 5 25 
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867 hsa-miR-924 11 11 5 7 
868 hsa-miR-92a 1,369 1,405 1,492 1,526 
869 hsa-miR-92a-1* 11 11 7 22 
870 hsa-miR-92a-2* 9 6 8 7 
871 hsa-miR-92b 496 465 520 517 
872 hsa-miR-92b* 9 15 4 10 
873 hsa-miR-93 54 35 47 47 
874 hsa-miR-93* 16 23 6 11 
875 hsa-miR-933 29 24 26 11 
876 hsa-miR-934 20 5 11 12 
877 hsa-miR-935 8 23 4 22 
878 hsa-miR-936 31 12 12 23 
879 hsa-miR-937 11 17 7 17 
880 hsa-miR-938 7 10 5 8 
881 hsa-miR-939 13 17 6 16 
882 hsa-miR-940 63 63 64 42 
883 hsa-miR-941 7 4 4 8 
884 hsa-miR-942 7 7 6 7 
885 hsa-miR-943 7 15 11 9 
886 hsa-miR-944 8 8 11 8 
887 hsa-miR-95 5 7 5 12 
888 hsa-miR-96 7 14 7 4 
889 hsa-miR-96* 6 4 7 9 
890 hsa-miR-98 18 26 12 19 
891 hsa-miR-99a 19 24 33 51 
892 hsa-miR-99a* 5 11 9 15 
893 hsa-miR-99b 57 61 68 65 
894 hsa-miR-99b* 3 7 5 18 
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Abstract 
SYNERGISTIC EFFECTS OF GARCINOL AND GEMCITABINE IN ENHANCING 
THERAPEUTIC EFFICACY IN PANCREATIC ADENOCARCINOMA CELLS AND ITS 
EFFECT ON MICRORNA PROFILE 
  
by 
MANSI PARASRAMKA 
August 2010 
 
Advisor:   Dr. Smiti V Gupta 
Major:      Nutrition and Food Science 
Degree:    Doctor of Philosophy 
 
Human Pancreatic Cancer (PaCa) is one of the most hostile and fourth leading 
cause of cancer deaths in the United States. Current standard chemotherapeutic agent 
for advanced PaCa is gemcitabine, a cytotoxic nucleoside analogue which results in 
modest response due to high degree of inherent and acquired chemo resistance. 
Forthcoming evidence strongly supports that non-nutritive food components have 
therapeutic benefits attributable to pleiotropic effects including down-regulation of 
survival signaling and simultaneously activating multiple death pathways in tumors. 
Garcinol from the plant Garcinia indica have exhibited anti-inflammatory, antioxidant, 
and anticarcinogenic activity in several cancer types including colon, tongue, breast, 
skin and liver. This study aims to test 1) therapeutic efficacy of garcinol against PaCa 
(BxPC-3 and Panc-1) cells 2A) its role in dietary interactions with curcumin and 2B) 
drug sensitization with gemcitabine and 3) identify microRNA targets in PaCa cells on 
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treatment with garcinol and gemcitabine. The activity of transcription factor nuclear 
factor – κB (NF-κB) has long been associated with pancreatic tumor growth and 
angiogenesis, playing an important role in cell survival, chemotaxis and inflammation. 
Angiogenesis, a very crucial process in tumorigenesis requires the interplay between 
NF-κB with other proangiogenic and antiangiogenic factors such as vascular endothelial 
growth factor (VEGF), Interleukin-8 (IL-8) and matrix metalloproteinase (MMP-9). We 
hypothesize that molecular targeting of critical signaling pathways (NF- κB, VEGF, IL-8 
and MMP-9) with gemcitabine in combination with garcinol may improve efficacy by 
enhancing the signaling response to treatment. Emerging evidence suggests that 
microRNAs regulate carcinogenesis by controlling gene expression either by their tumor 
suppressor or oncogenic abilities. We observed that garcinol individually or in 
combination with curcumin or gemcitabine exhibited potent anticancer abilities in PaCa 
cells by down-regulating cancer promoting pathways and up-regulating the tumor 
suppressor mechanisms. Decreased NF- κB activity was observed in both cell lines in 
combination treatment along with significantly reduced levels of angiogenic factors 
MMP-9, VEGF, IL-8 and PGE2. We also performed target analysis after treatment to 
identify those microRNAs that regulate several cancer signaling pathways. We 
observed a downregulation in expression of oncogenic miRNA – 21, - 196a and – 495 
along with upregulation of tumor suppressor miRNA – 638 and – 453 on treatment with 
garcinol alone or in combination with gemcitabine. Overall, our results demonstrate that 
garcinol and gemcitabine in combination have higher efficacy in modulating levels of 
various factors involved in tumorigenesis and have potential in chemotherapy against 
PaCa. 
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